8th Annual IBCN Symposium by Purdue University, Office of the Executive Vice President for Research and Partnerships

October 1, 2018 Dear Attendees, It is a pleasure for me to welcome you to the Eighth Annual International Breast Cancer Prevention Symposium, which is focusing on Technology, Engineering & Data Science for primary prevention. The Purdue University Center for Cancer research is very proud to support the Symposium and its mission. I would like to thank the co-chairs, Sophie LeliĂ¨vre, Connie Weaver, Martine Belanger, and Mary Beth Terry for organizing an outstanding program with experts from around the world. I'm confident that the presentations and discussions that will occur during this meeting will lead to greater collaborative interaction and ultimately enable the development of better prevention approaches for breast cancer. This year's symposium focus on primary prevention of cancer requires understanding how the environment influences the epigenome. New technologies are becoming readily available to gather vast amounts of data, and emerging models such as organs-on-a-chip will enable individualized cancer prevention. The symposium agenda contains many presentations of high interest and impact for prevention. The integration of these diverse topics including blood phosphoprotein identification of breast cancer and the impact of data science on prevention will provide the foundation for developing diverse collaborative interactions that will help develop novel and impactful prevention approaches. To enhance the transfer of ideas, the meeting traditionally has frank and open discussions of presentation topics. These discussions lead to new insights and pave the way for the development of new collaborations. I look forward to outstanding presentations and active participation by all. Thank you all for your attendance. Enjoy the beautiful environment, the outstanding scientific presentations and discussions, and the wonderful opportunity to develop new collaborations that will lead to processes to prevent the development of cancers. Sincerely,

Timothy L. Ratliff, Ph.D. Distinguished Professor, Comparative Pathobiology Robert Wallace Miller Director Purdue University Center for Cancer Research

Table of Contents Agenda- Page 2 Abstracts- Page 7 Bios- Page 33 Concept Paper- Page 71 Scientific Committee- Page 74 Poster List- Page 76 Registrants- Page 79 Sponsors- Page 85

Eighth International Breast Cancer Prevention Symposium: Engineering, Technology and Data Science for primary prevention Purdue University, West Lafayette, USA October 8-9, 2018 Co-Chairs: Sophie Lelièvre, Connie Weaver, Martine Bellanger, Mary Beth Terry Symposium Monday, October 8, 2018 Pfendler Hall, 715 W. State St, Deans Auditorium, Room 241 8:15-8:45 am

Registration and breakfast

8:45-9:00 am

Welcome by the co-chairs, the Purdue University Center for Cancer Research Director and Guests (the Mayor of Kumasi and students from Purdue University and the American University of Beirut)

9.00-9:40 am

Symposium Keynote: Andy Tao, PhD, Purdue University “Developing exosome phosphoproteins as breast cancer biomarkers: Promise and Challenges”

Session 1

Breast Cancer Prevention… from around the world Chair: Graciela Sabini, MD, Ministry of Health, Montevideo, Uruguay Co-Chair: Victoria Seewaldt, MD, PhD, City of Hope, CA

09:40-10:00 am

Beatrice Wiafe-Addai, MD, PhD, Peace and Love hospitals, Kumasi, Ghana “Prevention and early detection of breast cancer in LMICs: BCI/PLH model in education, research, awareness creation and screening.”

10:00-10:20 am

Nahla Hwalla, PhD, American University of Beirut, Lebanon “Nutrition and cancer: Reviewing the evidence”

10:20-10:40 am

Break

10:40-11:00 am

Song-Yi Park, PhD University of Hawaii, USA, “Diet and Breast Cancer Risk in the Multiethnic Cohort Study”

11:00-11:20 am

Marisa Fazzino, MD, Hospital Policial, Montevideo, Uruguay “Breast Cancer Prevention in Uruguay”

11:20-11:40 am

Charlotte Huet MD, PhD, Unicancer Rennes, and Caroline Abadie, MD, PhD, Institut de Cancérologie de l’ouest, Nantes, France “Genetic

predisposition to breast cancer: from screening to the health care management of very high risk women“

12:00-2:00 pm

Award Lunch Purdue Memorial Union, East Faculty Lounge. Room 240 Susan Bulkeley Butler Leadership Excellence Award lecture: Mary Beth Terry, PhD, Professor of Epidemiology, Columbia University “Breast cancer prevention in Young Women: Less (Family) History more Forecasting”

Session 2

Rethinking breast cancer prevention: Novel ways to monitor risk Chair: Mary Beth Terry, PhD, Professor of Epidemiology, Columbia University Co-Chair: Nora Artagaveytia, MD, PhD Universidad de la República, Montevideo, Uruguay

2:00-2:15 pm

Introductory remarks by Mary Beth Terry and Victoria Seewaldt

2:15-2:40 pm

Lothar Lilge, PhD, Senior Scientist, Princess Margaret Cancer Centre, Medical Biophysics, University of Toronto “Optical Breast Spectroscopy as alternative methods to monitor efficacy of Breast Cancer prevention strategies”

2:40-3:05 pm

Luis G. Carvajal-Carmona, PhD, Associate Professor, Department of Biochemistry and Molecular Medicine, School of Medicine, University of California Davis “An update on the role of homologous recombination genes in cancer risk: mutation prevalence in non-Caucasians and the role in gastro-intestinal malignancies”

3:05-3:20 pm

Break

3:20-3:45 pm

Andreas H Hielscher, PhD, Professor of Biomedical Engineering, Radiology (Physics) and Electrical Engineering, Columbia University "Dynamic Optical Tomography for Predicting Neoadjuvant Chemotherapy Outcome and Assessing Breast Cancer Risk"

3:45-4:10 pm

Jasmine McDonald, ScD, Assistant Professor, Department of Epidemiology, Columbia University “Can the postpartum period be a point of assessment for breast cancer risk?” 3

4:10-5:00 pm

Debate

5:30-8:00 pm

Poster Session and buffet DAUCH Alumni Center, 403 W. Wood Street, Prusiecki Banquet Room & Rudolph Living Room

Tuesday, October 9, 2018 Jerry S Rawls Hall, (RAWL), 100 S. Grant Street, Room 1086 8:00-8:30 am

(Registration- breakfast)

8:30-9:15am

Symposium Keynote on the future of data science: Sharon Ross, PhD, MPH, Division of Cancer Prevention, National Cancer Institute, NIH, USA “The promise and challenge of data science for cancer prevention.”

Special topic:

Nutrition and data science Chair: Connie Weaver, PhD, Nutrition Science, Purdue University

9:15-9:40 am

Min Zhang, MD, PhD. Department of Statistics, Purdue University, “New Statistical Tools for Integrative Analysis of Omics Data”

9:40 –10:05 am

Forum Discussion

Special topic:

Organs-on-a-chip for primary prevention research Chair: Leslie Reinlib, PhD, Breast Cancer & the Environment Research Program, National Institute of Environmental Health Sciences

10:10-10:30 am

5-minutes talks by biologists and Engineers followed by roundtable Sophie Lelièvre, PhD, DVM, LLMPH (Purdue University) "risk-on-a-chip for primary prevention research" Rabih Talhouk, PhD (American University of Beirut): “A Biomimetic Lab-on-a-Chip (LOC) device for studying cancer growth in ductal systems. A Prototype” Pierre-Alexandre Vidi, PhD (Wake Forest University) “Quantification of epithelial cell polarity using radial intensity profiles” Rahim Rahimi, PhD (Purdue University) "Rapid laser manufacturing of multi-layer microfluidic devices"

10:30-10:55 am

Forum discussion 4

10:55-11:10

Break

Session 4

Measuring epigenetic information for cancer risk assessment Chair: Sharon Ross, PhD, MPH, Division of Cancer Prevention, National Cancer Institute, NIH, USA

11:10-11:35 am

Pierre-François Cartron, PhD, Institut de Cancérologie de l’ouest, France “Role of epigenetic in the "Glyphosate+X=Breast cancer"

11:35-12:00 pm

Chongli Yuan, PhD, Chemical Engineering, Purdue University, USA, “Contribution of epigenetic factors to the acquisition of drug resistance in cancer cells”

12:00-12:25 pm

Rihab Nasr, PhD, American University of Beirut, Lebanon, “microRNA Expression in Ethnic Specific Early Stage Breast Cancer”

12:30-2:00 pm

Lunch on your own

2:00-3:00 pm

CATHERINE PEACHEY ORAL PRESENTATIONS (Graduate and postgraduate trainees) Chair: Marion Lee, PhD, The Center for Health and Community, University of California San Francisco, USA and Institute of Epidemiology and Preventive Medicine, National Taiwan University, Taiwan Nataly Naser Al Deen, American University of Beirut, Lebanon, “Dysregulated microRNAs in Early Onset Breast Cancer in Lebanon and their Association with Loss of Morphogenesis of Breast Epithelium in a 3D Culture Model” Rhonda Arthur, Albert Einstein College of Medicine, USA, “Body Fat and Risk of Breast Cancer in Postmenopausal Women with Normal Body Mass Index: A Secondary Analysis of the Women’s Health Initiative Randomized Clinical Trials and Observational Study” Dennis Cladis, Purdue University, USA, “Mineral and Phenolic Content in Representative Diets from Seven Countries for the International Breast Cancer and Nutrition Project” Farzaneh Atrian Afyani, Purdue University, USA, “Enhancing the Effect of Anticancer Drugs through Modifications of Nuclear Morphology”

Session 5

New technologies and data science for prevention interventions and implementation Chair: Martine Bellanger, PhD, EHESP School of Public Health, France Co-Chair: Parisa Tehranifar DrPH, Columbia University, Mailman School of Public Health NYC, USA

3:15-3:40 pm

Lauren Houghton, PhD, and Jasmine McDonald, PhD, Columbia University, NYC, USA “Mobilizing breast cancer research through smartphone apps”

3:40-4:05 pm

Sudha Sivaram, DrPH, MPH, Center for Global Health, National Cancer Institute, National Institutes of Health, Rockville, MD, USA “Using technology for cancer prevention and treatment: research opportunities and lessons from global settings”

4:05-4:20 pm

Break

4:20-4:45 pm

Angela Bradbury, MD, Division of Hematology-Oncology, Department of Medicine, The University of Pennsylvania, Philadelphia, PA “Innovative delivery models to increase access to genetic services”

4:45-5:10 pm

Marissa Burgermaster, PhD, Assistant Professor of Nutritional Sciences and Population Health, University of Texas at Austin “Precision Behavioral Nutrition: Improving Behavior Change Interventions with Patient-Generated Data”

5:10-6:00 pm

Debate- wrap

Abstracts

Centralization of cancer care: the journey to diagnosis of locally advanced breast cancer in Ghana 1. Abena Ofosuah Addai, M.D, PhD candidate. Breast Care International, Peace and Love Hospitals, N. N. Blokhin Russian Cancer Research Centre. 2. Beatrice Wiafe Addai, M.D, PhD. Breast Care International, Peace and Love Hospitals. Background: Over 60% of breast cancer cases at the Peace and Love Hospitals (PLH) are diagnosed at locally advanced stages. PLH just like other specialized cancer centers are located in the big cities of Ghana with limited access for women living in the communities. Methods: Semi-structured interviews were conducted with 8 locally advanced breast cancer patients receiving palliative care at PLH in Kumasi to find out the causes of delay in presentation at a cancer treatment center. Results: The least travel time for all was 45mins â&#x20AC;&#x201C; 1 hr. Some local clinics donâ&#x20AC;&#x2122;t offer specialized palliative services, so some of the women travel multiple times a week to PLH for wound dressing, for example, which is a service that PLH provides for free. Of the 8 women, three were referred more than two times in clinics close to where they reside and ended up defaulting treatment because of cost (transportation, investigations: if a patient doesnâ&#x20AC;&#x2122;t have copies of previous tests, they have to redo them at the new clinic). Two women had their first point of call being a herbal clinic and prayer camp. Two women defaulted orthodox treatment to try herbal. One woman defaulted surgery in 2016 and later presented locally advanced. Conclusions and Recommendations: These findings suggest that there is a high likelihood that patients will not follow through with medically indicated treatments for breast cancer due to factors that include distance, costs of repeating previous tests when referred, or cultural and religious practices that are tried first and may delay receiving medical treatments. To help improve services for cancer patients and reduce the number of treatment defaults, healthcare workers should be educated in basic oncology in order to refer patients effectively and quickly to specialized cancer centers. Holistic cancer treatment and support should be given to the women through their treatment journey in order to help women comply with orthodox treatment. Community based nurses can be trained in education/early detection (clinical breast screening) and end of life/palliative care (wound dressing) to help increase early stage presentation to a hospital instead of a herbal clinic or prayer camp as well as improve the quality of life of women on palliative care. 8

The national health insurance should cover a larger percentage of the cost of screening, diagnosis, treatment and rehabilitation of breast cancer treatment in order to reduce the financial toxicity of the disease on the women and reduce defaults due to the cost burden. More study needs to be done in order to fully understand the social behaviors and factors influencing late stage presentation of breast cancer in Ghana. Future study and evaluation on effectiveness after re-training of health care workers.

ENGINEERING IN VITRO MODELS TO STUDY THE SYNERGISM OF BREAST CANCER RISK FACTORS Chittiboyina, Shirisha(1); Rahimi, Rahim(2); Cosby, Cyan (3); Bai, Yunfeng(1); Ziaie, Babak(2,4, 5); Lelièvre, Sophie(1,2,5)

(1) Basic Medical Sciences; (2) Birck Nanotechnology Center; (3) Biological Sciences; 4) Electrical & Computer Engineering; (5) Center for Cancer Research, Purdue University

ABSTRACT: The microenvironment of the breast epithelium is greatly influenced by geneenvironment interactions that play a role in breast cancer. Reactive oxygen species (ROS) are a consequence of environmental exposures including poor diet that leads to oxidative stress (OS) under conditions of redox imbalance and influence gene expression, affect nuclear morphology to mimic alterations characteristic of cancer development and also change mammographic density, another risk factor for breast cancer, by activating fibroblasts in the microenvironment, leading to increased secretion of collagen I in the matrix. Our preliminary studies revealed that under acute ROS exposure, the breast epithelium produced in 3D cell culture displayed loss of polarity, a barrier against cancer development. Interestingly, ROS-induced altered nuclear morphology annunciating chromatin rearrangement and phenotypic changes was observed in both epithelial cells and fibroblasts. Our central hypothesis is that microenvironmental oxidative stress in synergy with altered matrix stiffness promotes breast cancer risk. To test our hypothesis we are using 3D cell culture models that comprise non-neoplastic human mammary epithelial HMT-3522 S1 cells and human mammary fibroblasts HMS32-hTERT. Exposure to 250 μM H2O2 for four hours and 25 μM H2O2 for 10 days, induced acute and chronic OS respectively. To test the effect of matrix stiffness S1 cells were cultured on collagen I (coated with laminin 111 to induce differentiation) at 770 Pa (average normal matrix stiffness), 1000 Pa and 1400 Pa (stiffness associated with increased risk), and fibroblasts (cultured separately) were embedded in collagen I matrices of similar stiffness range. Phenotypic changes were measured on a per cell basis using cell shape (phalloidin staining of the actin skeleton) and nuclear morphometry (DAPI staining of DNA). Increased stiffness led to significantly less circular nuclei (a change in shape) but did not change the size (area) of the nucleus in S1 cells. Fibroblasts displayed a higher proportion of dendritic and flattened cells compared to cells with elongated shape. Higher stiffness did not change the circularity but increased nuclear size in fibroblasts. Interestingly in S1 cells (in 770 Pa) both acute and chronic ROS induced an increase in nuclear size that was accompanied with decreased circularity. Thus, ROS and matrix stiffness 10

influence epithelial cells and stromal cells independently with nuclear changes typically seen with cancer onset. To better understand the effect of these two microenvironmental features on the risk of cancer we will coculture epithelial cells on fibroblasts embedded in collagen I matrix and expose them to a gradient of ROS using a microfluidics-based tissue-chip with integrated magnetic biosensors to monitor changes in matrix stiffness that includes hemichannels laser etched on paper, to mimic ductal geometry(that affects nuclear morphology), as seen in vivo and with a density of holes for the epithelium to sense the matrix stiffness underneath.

MINERAL AND PHENOLIC CONTENT IN REPRESENTATIVE DIETS FROM SEVEN COUNTRIES FOR THE INTERNATIONAL BREAST CANCER AND NUTRITION PROJECT Cladis, Dennis(1); Martin, Berdine(2); Naja, Farah(3); Donangelo, Carmen(4); Shyur, Lie-Feng(5); Yang, Felil(6); Wiafe-Addai, Beatrice(7); Welch, Ailsa(8); Weaver, Connie(9)

(1)Purdue University, USA; (2)Purdue University, USA; (3)American University of Beirut, Lebanon; (4)Universidad de la Republica, Uruguay; (5)Academia Sinica, Taiwan; (6)Fu-Jen Catholic University, Taiwan; (7)Peace and Love Hospital, Ghana; (8)University of East Anglia, United Kingdom; (9)Purdue University, USA

ABSTRACT: Objectives: Breast cancer (BC) is the #1 cause of cancer mortality in women and global rates are rising, especially in low and middle income (LMI) countries. The etiology of BC is influenced by environmental factors, including diet, that alter the epigenome and can result in disease development. However, food composition and nutrient databases are scarce in LMI countries, making the dietary influence on BC etiology difficult to understand. Thus, the objective of this pilot study was to collect and analyze mineral and phenolic intake in representative diets and urine samples from women participating in the International Breast Cancer and Nutrition collaboration.

Methods: In the first phase of this study, teams from each country collected, homogenized, froze, and shipped 1-2 representative diets to our lab for analysis of minerals (Ca, Mg, Na, K, Cu, Fe, and Zn) and phenolics. In the second phase, teams from each country are recruiting two women. Each woman completes a 24-hour diet record, collects her diet from that day, and submits the diet as well as a fasting blood and urine sample at a clinical visit the following morning. Diets are processed as in phase I, while urine samples are acidified, frozen, and shipped to us. Upon arrival, urine and lyophilized diet samples are analyzed for minerals by ICP-OES and phenolics via solid phase extraction and colorimetric detection using the Folin method.

Results: To date, seven partner countries have completed phase I, with four completing both phases. Mineral intakes for representative diets collected in phase I showed considerable variation for calcium (463-922 mg/d), potassium (1246-2003 mg/d), magnesium (186-243 mg/d), 12

sodium (1791-2976 mg/d), copper (680-1040 ug/d), iron (5.7-8.7 mg/d), and zinc (6.5-7.4 mg/d), though few diets met the US Dietary Reference Intake (DRI). Total phenolic intake for phase I diets ranged from 449-1246 mg/d. Mineral and phenolic content in phase II diets mirrored those collected in phase I.

Conclusions: Our ability to successfully collect and analyze minerals and phenolics in representative diets from across the globe proved the feasibility of this project. Future studies will expand upon this pilot study to relate dietary intake to nutrigenomics and the etiology of BC.

Enhancing the Effect of Anticancer Drugs Through Modifications of Nuclear Morphology Farzaneh Atrian Afyani1, Rahim Rahimi2, Manuel Ochoa2, Christopher Duffey1, Weijian Gong1, Babak Ziaie2,3 and Sophie A. LeliĂ¨vre1,2,3 (1) Department of Basic Medical Sciences, (2) Birck Nanotechnology Center, (3) Center for Cancer Research, Purdue University, West Lafayette, IN

Cancers have the ability to develop resistance to traditional therapies. Identifying pathways that predict cancer cellsâ&#x20AC;&#x2122; response to drugs would tremendously help the design of new therapeutics and eliminate resistance. We have shown previously that tumors cultured in engineered curved geometry (mimicking ducts in which tumors grow) display significantly different drug sensitivities compared to those cultured on a flat surface, and that a major morphological difference between these two culture conditions involved nuclear morphometry (e.g., size, circularity). Our hypothesis is that mechanical cues from the tumor microenvironment could alter nuclear features that control the phenotypic response of cancer cells to antiproliferative drugs. Morphological analysis of the cell nucleus in the curved geometry as well as hydrogel and hanging drop systems (with amorphous geometry) showed that only nodules in the curved set-up have nuclear shape (circularity) and size (area) similar to that of tumors in vivo. In addition, we compared the sensitivity of triple negative breast tumors to cisplatin, with proven efficacy in the clinics, and SAHA, an epigenetic drug that so far failed in breast cancer treatment. Our results suggest higher sensitivity to cisplatin and lower sensitivity to SAHA of breast cancer cells cultured in ductal-like geometry compared to the amorphous systems. Moreover, culture conditions that lead to increased nuclear area also promoted higher cell sensitivity to the antiproliferative drugs. To evaluate the importance of nuclear morphometry in drug response we treated cancer cells with latrunculin that increases nuclear area and circularity. Under this condition, the number of apoptotic and growth-arrested cells increased following treatments with cisplatin and SAHA, respectively. Nuclear morphometry was also modified by spreading cells over a fibronectin coated micropatterned surface. Cisplatin treatment revealed higher sensitivity of cells with bigger compared to smaller nuclear area. The nuclei with increased area had the highest number of 53BP1 foci, representing DNA double strand breaks, hence confirming a positive link between nuclear area and drug sensitivity. To validate the relationship between drug sensitivity and nuclear morphology in a more physiologically relevant manner we cultured tumor cells in collagen I matrix with adjustable stiffness to recapitulate forces sensed by nuclei in vivo. Nuclear morphometric analysis indicated that high matrix stiffness (2020 Pa, a rigidity similar to human breast tumors) was accompanied with decreased nuclear size. Accordingly, the percentage of cancer cells death induced by cisplatin was significantly lower in 2020 Pa compared to the low 14

matrix stiffness (900 Pa, a rigidity similar to normal human breast tissue), suggesting the involvement of mechanotransduction in controlling sensitivity to chemotherapy. Interestingly, silencing NuMA, a nuclear matrix protein that is involved in higher order chromatin organization, modified nuclear morphometry in a matrix stiffness dependent manner. In comparison with 900 Pa, silencing NuMA in tumors generated in 2020 Pa decreased nuclear area. Moreover, the sensitivity of NuMA-silenced cells to cisplatin was significantly decreased in stiffer collagen compared to the softer condition. Our findings suggest that NuMA could be a nuclear mechanosensor controlling pathways relevant for drug sensitivity by transferring mechanical cues from the tumor microenvironment to the genome.

Enhancement of Bioactive Compounds from Black Grape Extract using Pulsed Electric Field Treatment T. Jeya Shree1, V. Gowri Sree1, Lakshya Mittal2,* and Raji Sundararajan2 1Division

of High Voltage Engineering, Department of Electrical and Electronics Engineering, College of Engineering Guindy, Anna University, Chennai 600025 2School

of Engineering Technology, Purdue University, Indiana, USA

Presenting Author

ABSTRACT:

Background: Grapes, one of the world’s largest fruit crops and most commonly consumed fruits in the world, are rich in antioxidants and phytochemicals. Grape extract comprises several bioactive compounds, mostly represented by polyphenols. Polyphenol has anti-oxidant, antiinflammatory, anti-platelet aggregation, anti-carcinogenic, cartilage-protective, and anti-aging properties. In this study the effects of pulsed electric field on the extraction of polyphenols from grapes is investigated.

Materials & Methods: Black grape juice extract was subjected to pulsed electric field (PEF). The effects of process parameters including electric field strength (2.5–15 kV/cm), treatment time (100 ms), pulse width (100 µs), number of pulses (5-15) and pulse polarity (unipolar) on total phenol content and antioxidant capacity were studied. Total phenolic content was measured using Gallic acid standard and antioxidant capacity through the inhibition of DPPH (1,1-diphenyl2-picrylhydrazyl) radical.

Results: Black grape juice extract exhibited high retention of polyphenol and antioxidant capacity when high electric field strengths and more pulses were applied, compared to unpulsed samples. Maximal relative phenol content (7.341 mgGAE/ml) and antioxidant capacity retention (82.47%) were obtained when PEF treatments were set up at 10 kV/cm for 100 ms using 100 µs, 15 unipolar pulses. 16

CONCLUSION: The effect of PEF at 5 kV/cm for 100 ms in unipolar 100 Îźs pulses, on the main bioactive compounds and antioxidant capacity of black grape extract was investigated and compared to soxhlet extraction (70 Â°C for 8 hrs). PEF treated black grape juice extract showed higher total phenolic content and antioxidant levels than the untreated extract. Hence, application of PEF may be appropriate to achieve nutrition rich extract, and to enhance valueadded products from foods and/or agricultural matrix.

MEDICAL APLICATION: Even though there are several cancer treatments, the death rate of cancer patients is 8.8 million in 2016. There are inoperable, recurrent, and radio- and chemoresistant cancers that do not respond well to the current standard of cure. Thus, there is a critical need for safe, effective, yet affordable alternate techniques for the various types of cancers. Chemotherapy is the most commonly used cancer therapy. There are several side effects accompanied with chemotherapy. Invent of natural anticancer drugs paved a way for cancer chemotherapy with no or less side effects. The use of natural extracts that we use in day to day life is an excellent alternative for chemical drugs used in cancer treatment. To serve this purpose polyphenol rich PEF treated grape extract which has higher antioxidant and anticancer activity can be used.

DIELECTRICALLY-ACCURATE TISSUE SIMULATING MATERIALS FOR A HETEROGENEOUS BREAST MRI PHANTOM Krause, Liesl(1)

(1)Purdue Polytechnic, USA

ABSTRACT: MRI is more sensitive than other methods for diagnosing breast cancer, especially in patients with dense, predominantly fibrous breast tissue. However, developing new MR imaging protocols, particularly for high magnetic fields, requires safety testing to quantify specific absorption rate (SAR) from radio frequency (RF) heating. Before human testing, safety testing with anatomically and dielectrically accurate analogs, known as phantoms, must be performed to obtain preliminary results. Current MRI breast phantoms are either homogeneous or have barriers between tissue types, both of which are not representative of actual anatomies. To develop a heterogeneous, anatomically and dielectrically accurate breast phantom, gel tissue simulating materials (TSMs) were created. TSM dielectric properties were validated to be the same as known tissue dielectric properties with an open-ended coaxial probe. These materials can be combined to construct a heterogenous breast phantom that is more anatomically accurate than current models.

THE PCCR BIOINFORMATICS CORE: A GLANCE AT CAPABILITIES AND HIGHIMPACT PROJECTS Lanman, Nadia(1); Utturkar, Sagar(2); Dhawan, Deepika(3); Mohammed, Sulma(4); Ratliff, Timothy(5); Knapp, Deborah(6)

(1)Purdue University Department of Comparative Pathobiology, United States; (2)Purdue University Center for Cancer Research, United States; (3)Purdue University Department of Veterinary Clinical Sciences, United States; (4)Purdue University Department of Comparative Pathobiology, United States; (5)Purdue University Department of Comparative Pathobiology, United States; (6)Purdue University Department of Veterinary Clinical Sciences, United States ABSTRACT: The Purdue University Center for Cancer Research (PCCR) Bioinformatics Core performs a number of services for PCCR members such as scientific consulting, training, and performing high-quality bioinformatics analyses. During consultations, the core aids in experimental design and manuscript/grant preparation. The core is composed of two full-time staff members and currently mentors two graduate research assistants and one undergraduate researcher. Since its inception in 2015, the core has worked with 34 PCCR faculty on a number of different analyses. Analyses performed so far include RNA-seq, scRNA-seq, ChIP-seq, whole genome CRISPR/Cas9, WGS, CLASH, data integration, and custom analyses. Here, we highlight two examples of RNA-seq and WGS analyses performed with the canine model system. In the first example, we characterized the progression of triple-negative DCIS (TN-DCIS) to breast cancer to identify the key cancer genes, signaling pathways and regulatory processes. Our analysis showed that Wnt signaling components and other pathways induced by Wnt family members distinguish the TN-DCIS from invasive cancer. In another example, canine lymphoma samples were characterized using WGS to identify the somatic mutations, indels, and copy-number variations. Genes that are altered across multiple lymphoma samples were analyzed and top mutated genes in >50% samples include LGALS3, ITGB7, BCL11B, TRAF3 which could be the possible cancer driver genes. These canine models closely resemble human cancer and comparative analysis with TCGA data should prove useful for vaccines and therapeutic development that can be translated into human clinical trials.

Dysregulated microRNAs in Early Onset Breast Cancer in Lebanon and their Association with Loss of Morphogenesis of Breast Epithelium in a 3D Culture Model Nataly Naser AL Deen1, Shirisha Chittiboyina2, Farah Nassar3, Humam Kadara4, Rihab Nasr5*, Sophie LeliĂ¨vre2*, Rabih Talhouk1* 1 Departments of Biology, Faculty of Arts and Sciences,3Internal Medicine, 4 Cancer and Stem Cell, 5Anatomy, Cell Biology and Physiological Sciences, Faculty of Medicine, American University of Beirut, 2Department of Basic Medical Sciences, College of Veterinary Medicine, Purdue University. (*Corresponding Authors) Breast cancer constitutes one third of all female cancers in Lebanon, with an alarming high percentage diagnosed under the age of 40, 22% of cases in Lebanon compared to 6% in the West [1]. High risk and differential susceptibility in our population is potentially attributed to epigenetic alterations linked to the environment and notably, to a westernized way of life rather than to genetic alterations [2-4]. microRNAs (miRNAs), small non-coding RNAs, can serve as highpotential biomarkers by virtue of their dysregulation in cancer not only in tissues but also in biological fluids. In order to investigate the mechanisms of breast cancer development and identify biomarkers for early detection and prognosis, Nassar et. al, have profiled miRNAs in breast tumors and normal adjacent tissues from Lebanese breast cancer patients and compared those to matched American breast cancer patients [5,6]. The results from the Lebanese patients showed 21 exclusively dysregulated miRNAs (e.g. miR-31, 362-3p, and 663) and four miRNAs with different expression manner compared to American patients (e.g. miR-1288-star and 324-3p). In the present project we wish to investigate whether some of the dysregulated miRNAs from the subset of the Lebanese patients below the age of 40, if sensitive to environmental risk factors, might also be a source of biomarkers to evaluate the risk for cancer development. Our central hypothesis is that dysregulated miRNAs may increase risk of breast carcinogenesis by disrupting breast epithelial polarity, transitioning cells from phenotypically normal epithelium to premalignant phenotype. To address our hypothesis, we used 3D cell culture conditions that permit physiologically relevant differentiation of a risk progression series: Non-neoplastic mammary epithelial HMT-3522 S1 cells form a fully polarized epithelium, S1-185 cells form an epithelium lacking apical polarity (a necessary step for tumor development) and S1-Cx43KO cells (S1 cells silenced for gap junction Cx43) form an epithelium devoid of apical polarity and containing proliferating cells [7,8]. Cells were placed under chronic oxidative stress, an environmental cancer promoting factor, induced via treatment with hydrogen peroxide (25 ÂľM H2O2 for 4 weeks). Using in silico analysis of the miRNAs from the Lebanese study, we have first identified from our young patient populationsâ&#x20AC;&#x2122; miRNome (under the age of 40), 15 miRNAs involved in early initiation events of breast cancer that contribute to loss of acinar morphogenesis and can be implicated in oxidative stress. Eight of these miRNAs are upregulated, of which miR492, 638, 663, 2861 and 3960 are exclusive to the Lebanese population, while miR-200c, 183 and 182 are commonly upregulated in both Lebanese and U.S. populations. miR-145, 125b, 100, 13920

5p, 99a, 126 and 130a are commonly downregulated among both populations. Moreover, using Ingenuity Pathway Analysis (IPA), we have linked these miRNAs to their validated mRNA targets and the underlying pathways involved in this miRNA-mRNA network according to pathways of interest (i.e., oxidative stress response, epithelial polarity, breast cancer, EMTâ&#x20AC;Ś). These mRNA targets were then compared to the actual mRNA microarray results from our Lebanese patients below the age of 40, whereby several targets were in common between both validated (IPA) and actual (patient) mRNAs (e.g. for miR-2861 targets: GSTM1, GSTM4, GSTT1 and for miR-145 targets: CLINT1, EIF4E, IRS1, MDM2, MYC). Acini from the risk progression series have now been prepared for miRNA-Sequencing (underway) to identify which among the 15 selected miRNAs are associated with increased risk as measured by loss of polarity, cell cycle activity and changes in the morphometry of the cell nucleus. Indeed, our preliminary findings show that acute oxidative stress (i.e., induced by 250 ÂľM H2O2 for four hours) leads to loss of polarity in HMT3522 S1 epithelium. We aim to identify, through the ongoing miRNA-Sequencing, a panel of common miRNAs between our young population and the 3D risk progression series, to decipher the role of the interplay between miRNA expression, morphological disruption and oxidative stress in breast cancer leading to early breast cancer onset.

METABOLIC REPROGRAMMING OF THE BREAST CONTRIBUTES TO A CANCERPROMOTING MILIEU Marino, Natascia (1); German, Rana(2); Rao, Xi(3); Xuei, Xiaoling(4); Wan, Jun(5); Liu, Yunlong(6); Sandusky, George(7); Jacobsen, Max(8); Cao, Sha(9); Storniolo, Anna Maria(10)

(1-10)Indiana University School of Medicine, USA;

ABSTRACT: In addition to the accumulation of pro-oncogenic mutations in the epithelial cells, the tumorigenic process involves the dysregulation of the interactions between the epithelial cells and their microenvironment, as well as alterations within the microenvironment itself. The latter is composed of endothelial cells, immune cells, fibroblasts, unaffected epithelium, and adipocytes. Increasing evidences support that cell transformation progresses in a potentially cancer-promoting microenvironmental context, also known as field cancerization model. Therefore, it is critical to investigate changes occurring in both the epithelial compartment and the surrounding microenvironment to understand how breast cancer initiates. In our preliminary study, we analyzed the transcriptome profile of microdissected breast tissue compartments (epithelium, stroma and adipose tissue) from tissue biopsies obtained from precancer women, who donated their histologically normal tissue two-to-five years before breast cancer diagnosis, and matched healthy control donors. In the pre-cancer breast, we detected a significant increase in genes regulating lipid metabolism (triacylglycerol degradation, fatty acid transport, and lipolysis) in the breast epithelium and a significant reduction in genes associated with immune cells homing in the stroma. The adipose tissue showed also increase in genes involved in metabolic activation and decrease in immune response genes. Overall, our findings suggest that fatty acids-driven metabolic reprogramming of the breast together with a reduction in immune response may promote the formation of a field cancerization. Understanding the changes occurring in the cancerized field is critical for elucidating 1) the involvement of microenvironment in cancer initiation 2) the role of histologically normal yet genetically altered surgical margin in risk of disease recurrence upon lumpectomy for early breast cancer diagnosis, and 3) the mechanisms of field cancerization in the contralateral breast.

PROSPECTIVE RANDOMIZED STUDY OF METFORMIN FOR BREAST CANCER PREVENTION IN OVERWEIGHT/ OBESE WOMEN Marino, Natascia (1); Ballinger, Tarah(2); Mina, Lida(3); German, Rana(4); True, Jason(5); Stamakin, Christopher(6); Cao, Sha(7); Storniolo, Anna Maria(8)

(1-8)Indiana University School of Medicine, USA

ABSTRACT: In epidemiologic studies, the oral antidiabetic medication metformin is associated with reduced cancer risk and cancer- related mortality. It is hypothesized that metformin might reduce breast cancer risk in obese or overweight women by improving metabolic factors and reducing proliferative pathway signaling. The purpose of this study is to investigate the effect of metformin on inflammatory and proliferative pathways in breast tissue, in an effort to better understand how we might prevent obesity- related carcinogenesis in the breast. 24 obese or overweight (BMI â&#x2030;Ľ 25), postmenopausal women at increased risk for breast cancer based on family history or personal history of breast cancer or atypical hyperplasia were randomized to either metformin (850 mg BID) or placebo for 12 months. Pre- and post-treatment mammographic breast tissue density, breast tissue proteomic profile, and serum biomarkers (IGF-I, IGF-II, Leptin, IL6, IL10, adiponectin, leptin, IGFBP3) were assessed. Of 24 women randomized, 18 completed the study. Participants receiving metformin showed no significant changes in breast density and in the measured serum biomarkers between pre and post-treatment or in comparison with the placebo group. RPPA-based proteomic analysis of the breast tissue cores showed a reduction of the activated form of the mTOR-related protein, phospho-Rictor (T1134), a decrease of the anti-apoptotic factor, Annexin VII, and an increase of ER-Golgi transport molecule COG3. Metformin treatment produced minor changes to proliferation marker c-Abl, whose level decreased after 12 months of metformin treatment as compared with the baseline. Our preliminary data suggest that metformin treatment does not affect the circulating biomarkers evaluated in this study. However, metformin has a direct effect on the breast tissue by reducing mTOR pathway, proliferation, and promoting apoptosis. Further investigation is required to broaden our understanding of the mechanism of protective action of this antidiabetic agent.

Body Fat and Risk of Breast Cancer in Postmenopausal Women with Normal Body Mass Index: A Secondary Analysis of the Women’s Health Initiative Randomized Clinical Trials and Observational Study Rhonda Arthur, PhD*1, Neil M. Iyengar, MD*2,3, JoAnn E. Manson, MD, DrPH4, Rowan T. Chlebowski, MD, PhD5, Candyce H. Kroenke, ScD6, Lindsay Peterson, MD7, Ting-Yuan D. Cheng, PhD8, Elizabeth C. Feliciano, ScD9, Dorothy Lane, MD10, Juhua Luo, PhD11, Rami Nassir, PhD12, Kathy Pan, MD13, Sylvia Wassertheil-Smoller, PhD3, Andrew J. Dannenberg, MD3, Thomas E. Rohan, MBBS, PhD, DHSc1, Affiliations: *Equal Contribution; 1Albert Einstein College of Medicine, Bronx, NY; 2Memorial Sloan Kettering Cancer Center, New York, NY; 3Weill Cornell Medical College, New York, NY; 4Brigham and Women’s Hospital, Harvard Medical School, Boston, MA; 5City of Hope National Medical Center, Duarte, CA; 6Kaiser Permanente, Oakland, CA; 7Washington University in St. Louis; St. Louis, MO; 8University of Florida, Gainesville, FL; 9Stony Brook University School of Medicine, Stony Brook, NY; 10Indiana University, Indianapolis, IN; 11University of California, Davis, CA; 12Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center. Corresponding author: Rhonda Arthur Department of Epidemiology and Population Health Albert Einstein College of Medicine, 1300 Morris Park Ave. Bronx, NY 10461 Tel.: 001-718-430-3038 Fax: 001-718-430-8653 Email: rhonda.arthur@einstein.yu.edu ABSTRACT Background: Obesity, which is characterized by excess body fat, is positively associated with risk of postmenopausal breast cancer, including estrogen receptor (ER)-positive breast cancer. However, it is unknown whether excess body fat is associated with increased risk of breast cancer among women with a normal body mass index (BMI; 18.5 to <25.0 kg/m2). In this secondary analysis, we examined the association between body fat measured using DXA and breast cancer risk among postmenopausal with normal BMI from the Women’s Health Initiative (WHI) cohort. Methods: This study comprised 3460 women aged 50 to 79 years, from the WHI Observational study and the clinical trials groups, who had normal BMI at enrollment. Participants were recruited into the study from 1993 to 1998. DXA-derived body fat was measured at baseline and at four follow-up visits at 3 designated US centers. Information on demographic data, medical history and lifestyle factors was collected at baseline using self-administered 24

questionnaires while anthropometric measures were taken by trained staff. Invasive breast cancers were confirmed via central review of medical records by physician adjudicators. After a median follow-up of 16 years, 182 incident breast cancers (including 146 ER-positive) had been ascertained. Blood analytes were collected at baseline for subsets of participants. Multivariable hazard ratios (HR) and 95% confidence interval (CI) for the associations of the baseline and follow-up DXA-measures with risk of invasive breast cancer were estimated using Cox proportional hazards regression. Adjusted geometric mean serum concentrations of selected analytes by trunk fat were also estimated. Results: Compared to those in the lowest quartiles, women with whole body fat, whole body fat percent and trunk fat in the highest quartiles had increased risk of invasive breast cancer (1.89; 95% CI 1.21-2.95, 1.79;1.14-2.83 and 1.88; 1.18 to 2.98, respectively). These body fat measures were also positively associated with risk of ER-positive breast cancer (HR: 2.21; 95% CI 1.23-3.67, 2.17; 1.29-3.66 and 1.98; 95% CI 1.18-3.31, respectively). Similar positive associations were observed in time-dependent covariate analyses. Circulating insulin, C-reactive protein, interleukin-6, leptin and triglycerides were higher, while HDL-cholesterol, and sex hormone binding globulin were lower in the uppermost versus lowest quartile of trunk fat (P <0.05). Conclusions: This study demonstrated that, despite having a normal BMI, excess high body fat was associated with increased risk of invasive breast cancer among postmenopausal women. These findings suggest that the current categorization of normal BMI may not adequately predict the risk of breast cancer in postmenopausal women.

ENGINEERING PLATFORMS TO INVESTIGATE CANCER METASTASIS Libring, Sarah(1); Hakim, Mazin(2); Hopkins, Kelsey(3); Jun , Brian(4); Vasiukhina, Anastasiia(5); Luis Solorio(6)

(1-6) Purdue Engineering, Purdue University, West Lafayette, USA

ABSTRACT: The tumor microenvironment is a complex milieu of cells, extracellular matrix (ECM) proteins, and soluble signaling factors that drive phenotypic changes in cancer cells during tumor growth and metastasis. It is a challenge to determine how these microenvironmental elements act individually and in concert to drive cancer cell responses including migration, proliferation, or dormancy. A better understanding of the cancer milieu could enable the creation of patientspecific model tumors for pre-clinical drug screening, or as part of precision medicine strategies. Furthermore, an effective model system could aid in the selection of appropriate chemotherapeutic agents and dosing regimes, allowing for the development of controlled release systems that can avoid systemic toxicity and improve patient outcomes. The Solorio research group has developed modular 3D tissue engineering platforms to independently evaluate the role of the ECM composition, protein conformational structure, and other (noncancer) cell components in cancer cell metastasis. These 3D environments can be utilized for the expansion of patient-derived cancer cells while retaining the cellular heterogeneity essential to allowing effective personalized drug screening. As effective chemotherapeutic drug dosages are identified, medical imaging is a critical element of designing systems for targeted, controlled drug delivery. To this end, diffusion weighted magnetic resonance imaging techniques are being utilized to evaluate the effects of local tissue properties on chemotherapeutic drug release from in situ forming polymeric implants. Ultimately, the use of next-generation technologies will enable better preclinical analysis and inform the design of safer, more effective therapies.

Engineering in vitro techniques to identify risk factors for breast cancer Shirisha Chittiboyinaac, Rahim Rahimibc , Cyan Cosbyd, Yunfeng Baia, Babak Ziaiec,e, Sophie A. Lelièvreace aDepartment

of Basic Medical Sciences, , bDepartment of Electrical and Computer Engineering, , cBirck Nanotechnology Center, Discovery Park, , dDepartment of Biological Sciences, , e Center for Cancer Research, Purdue University, West Lafayette, IN 47906

on the risk of cancer we will coculture epithelial cells on fibroblasts embedded in collagen I matrix and expose them to a gradient of ROS using a microfluidics-based tissue-chip with integrated magnetic biosensors to monitor changes in matrix stiffness that includes hemichannels laser etched on paper, to mimic ductal geometry(that affects nuclear morphology), as seen in vivo and with a density of holes for the epithelium to sense the matrix stiffness underneath.

PROTEOMIC ANALYSIS REVEALS AN EXTRACT OF THE PLANT LIPPIA ORIGANOIDES TARGETS MITOCHONDRIAL METABOLISM IN TRIPLE-NEGATIVE BREAST CANCER. Raman, Vishak (1); Aryal, Uma(2); Hedrick, Victoria(3); Ferreira, Rodrigo(4); Fuentes Lorenzo, Jorge Luis(5); Stashenko, Elena(6); Levy, Morris(7); Levy, Maria(8); Camarillo, Ignacio (9)

(1) Department of Biological Sciences; (2) Purdue Proteomics Facility; (3) Purdue Proteomics Facility; (4) Department of Biological Sciences; (5) Universidad Industrial de Santander, Colombia; (6) Universidad Industrial de Santander, Colombia; (7) Department of Biological Sciences; (8) Department of Biological Sciences; (9) Department of Biological Sciences ABSTRACT: Triple-negative breast cancer is an aggressive subtype of breast cancer with low 5year survival rates, high 3-year recurrence rates, and no known therapeutic targets. Recent studies indicated triple-negative breast cancers possess an altered metabolic state with higher rates of glycolysis, mitochondrial oxidative phosphorylation, and increased generation and utilization of tricarboxylic acid cycle intermediates. Here we utilized label-free quantitative proteomics to gain insight into the anti-cancer mechanisms of a methanolic extract from the Central American plant Lippia origanoides on MDA-MB-231 triple-negative breast cancer cells. The L. origanoides extract dysregulated mitochondrial oxidative phosphorylation by targeting Complex I of the electron transport chain and suppressed cellular metabolism by targeting key tricarboxylic acid cycle enzymes and mitochondrial lipid and amino acid metabolic pathways. Our study also revealed treatment with the extract activated the stress response, and pathways related to cell cycle progression and DNA repair. Overall, our results reveal new compelling evidence that the extract from Lippia origanodes triggers rapid irreversible apoptosis in MDAMB-231 cells by effectively â&#x20AC;&#x2DC;starvingâ&#x20AC;&#x2122; the cells of metabolites and ATP. We continue to study the specific bioactive components of the extract in the search for novel, highly effective mitochondrial inhibitors to selectively target triple-negative breast cancer.

Unmet needs of breast cancer survivors in Africa: needs assessment for developing survivorship services in Ghana and Tanzania Authors: 1Susannah Stanway, MD MBChB MRCP MD MSc, 2. Beatrice Wiafe Addai, MD PhD, drwiafe@gmail.com, 3. Nazima Dharsee, MD, 4.Amanda J Shewbridge, RGN MSc BSc (Hons), 5.Seth A Wiafe, PhD, MPH 6.Lisa E Murray, MRes, PGDip, RN, 6Geraldine O'Gara, BSc (Hons), R .6.Shyama Persaud, MSc, BA(Hons), BSc, and 6.Theresa Wiseman, PhD BSc (Hons) RN. 1Institute

of Clinical Research, London, United Kingdom, SW3 6JB; 2Peace and Love Hospital, Accra, Ghana; 3Ocean Road Cancer Center, Dar es Salaam, Tanzania, United Republic of; 4Guys and St Thomas' NHS Foundation Trust, London, United Kingdom; 5Loma Linda University, Loma Linda, California, United States, and 6The Royal Marsden NHS Foundation Trust, London, London, United Kingdom.

ABSTRACT While the incidence of breast cancer (BC) is increasing in Low-and Middle-Income countries (LMIC) with an 82% predicted increase in BC diagnoses in Tanzania by 2030, cancer survivorship in such countries where strongly held cultural beliefs act as a barrier to accessing treatment and support. Although the Breast Global Health Initiative has produced many documents on breast cancer management in LMIC, from scoping of services through to resource stratified guidelines, the most recent situation analysis, whilst extensive, didn't extend to scoping of survivorship services. In order to explore the feasibility of implementing a holistic needs assessment tool (HNA) and to capture the unmet needs amongst women who had received treatment for primary breast cancer at two centers in Ghana and Tanzania, the study used a mixed-methods design in two phases. The HNA forms part of the cancer recovery package, which is offered to all people at the end of cancer treatment developed as part of the UK National Cancer Survivorship Initiative. In Phase 1, focus group interviews were conducted with women following breast cancer treatment and staff to ask about their needs, scope current practice, resources and the potential challenges for developing survivorship services in Ghana and Tanzania. Interviews were transcribed, translated and analyzed using framework analysis. In Phase 2, the UK Holistic Needs Assessment was translated and adapted to be culturally sensitive so that it could be used as a way of scoping unmet need at the end of primary breast cancer treatment. Descriptive statistics were used to analyze this data. This paper reports on Phase 1. Emergent themes show the impact of having breast cancer on the women's lives. Themes include the impact of cultural beliefs on the experience of women with breast cancer, 30

accessibility of treatment and services, the impact on finance, the women's role in her family, and lack of communication and support. Women spoke about the importance of peer support from others with breast cancer and challenging cultural beliefs and practices. These findings suggest that understanding physical, financial, and psychological challenges breast cancer survivors face years even after completing treatment, could help improve how these needs are met in an evidence based and resource sensitive manner.

EXPLORATORY METABOLOMICS AND LIPIDOMICS BY MULTIPLE REACTION MONITORING PROFILING Xie, Zhuoer(1); Gonzalez, L. Edwin(2); Ferreira, Christina R.(3); Sobreira, Tiago Jose P.(4)

(1-4)Purdue University, United States;

ABSTRACT: Small molecules, including metabolites and lipids, play significant roles in disease and especially in cancer. Diagnosis, prognosis and therapy of certain diseases have been designed or improved with increasing knowledge from pathway analysis. However, discovery and characterization of small molecule metabolic functions has been a challenging task for years. Current exploratory methodologies for metabolomics and lipidomics are based on liquid or gas chromatography (LC or GC) coupled with high resolution mass spectrometry (HRMS) to generate a large set of data involving lengthy data acquisition, typically 30-60 min per sample. Even though many molecules can be distinguished by these methods, the highly laborious protocols for purification, identification, and validation results in loss or dilution of sample chemical information and high costs. To improve the speed and efficiency of exploratory metabolomics and lipidomics in covering the diversity of chemistry in these areas, multiple reaction monitoring profiling (MRM-Profiling) has been developed by examining the metabolome as a collection of functional groups. MRM-Profiling starts with a discovery phase, intended to interrogate the sample for a large number of functional groups by precursor scans (Prec) and neutral loss scans (NL) usually using a triple quadrupole mass spectrometer but without chromatography. For the second step of MRM-Profiling, the information from the Prec and NL scans is organized into lists of transitions (also called MRMs) that are used for the fast, specific and sensitive interrogation of individual samples. Data analysis by univariate and multivariate statistical methods is used to isolate the informative MRMs, which can then be further explored in structural studies and validated as biomarkers. The MRM-Profiling strategy benefits from the much smaller number of functional groups compared to the number of individual metabolites, most of which are still unknown, resulting in a much smaller data set acquired for analysis and shorter time needed for data collection. In general, the methodology produces ~103 times less data and saves instrument time by a factor of 10 compared to conventional LC-MS/MS methods. MRM-Profiling has been applied to Parkinsonâ&#x20AC;&#x2122;s disease, human polycystic ovarian syndrome, atopic dermatitis, and cardiac disease diagnosis, diet compliance and animal fertility prediction. Research on breast cancer focusing on diagnosis and mechanistic understanding of this condition using MRM-Profiling is now underway. 32

Bios, In Their Own Wordsâ&#x20AC;¦.

Caroline Abadie MD, PhD Institut de Cancérologie de l’ouest Nantes, France Caroline Abadie graduated from the Medical University of Montpellier, France and is a board-certified medical geneticist. She earned a Masters in Genetics at University Denis Diderot from Paris (European Magistère in Genetics) and worked as Assistant in Clinical Cancer Genetics in the Unicancer Rennes Centre and in the Rennes University Hospital. She is working as oncogeneticist in Clinical Cancer Genetics in the Institute of Cancer Research ICO (Institut de Cancérologie de l’Ouest) in Nantes. She is involved in diagnosis and management of patients with hereditary cancer predisposition, mainly high-risk women for breast cancer and chairs, since 2016, the Phare Grand Ouest group, a program for the health care management of patients with genetic predisposition to cancer, involving four regions in Western France. She is also member of the French GCC consortium (Groupe Génétique et Cancer) and the French PREDIR group labelled by the French National Cancer Institute (INCa) for kidney cancer predisposition.

Nora Artagaveytia

MD, PhD Department of Basic Medicine Faculty of Medicine University of Uruguay Montevideo, Uruguay Artagaveytia is Assistant Professor of the Department of Basic Medicine at the University Hospital of the Faculty of Medicine in Uruguay. She is a Medical Doctor specialized in Medical Oncology and obtained a PhD in Biomedical Science in 2006. She started her activity on education and research in the University in 1988. She had fellowships in molecular biology and fluorescent microscopy in France at different periods along her career. Her focus of research is prognostic and predictive factors in Breast Cancer, in particular hormone sensitivity and BRCA1 dysfunction. She integrates a working group with Geneticists and Anthropologists to address impact of Epigenetics and Ancestry in cancer development. Currently, the working group is focused on the integration of genomic and epigenetic data for breast cancer risk assessment and as prognostic markers. Her clinical activity is developed in the University Hospital at the Mastology Unit and in breast cancer genetic susceptibility testing. Since 2008 she is in charge of the Cryopreservation Area of the Tumor Biobank at the Army Forces of Uruguay which integrate the Latin American and Caribbean Biobank Network. Currently she is the Scientific Coordinator for Uruguay of the US-Latin America Cancer Research Network Projects.

Osei Assibey Antwi Chief Executive Kumasi Metropolitan Assembly Ghana Osei Assibey Antwi, the Kumasi Metropolitan Chief Executive is an eminent entrepreneur, a professional Administrator with over 20 years’ experience in senior management, a consummate politician of eminent distinction and a seasoned business executive of international standing with range of business interest in various sectors of the Ghanaian economy. Well respected by his peers and superiors as a philanthropist and a distinct family man, Osei Assibey Antwi believes in a shared-culture of life as the basis of humanity and the essence of leadership. Academic Qualifications He is a member of the prestigious International Professional Manager’s Association, (IPMA) of UK, Institute of Financial Accountants (IFA)-UK and holds an International Executive MBA degree in Marketing from Paris Graduate School of Management and a Graduate Diploma in Management Studies from the Institute of Commercial Management, UK. Political Leadership Role He was the Deputy Ashanti Regional Minister (December, 2006 – January, 2009). He acted as District Chief Executive of Adansi South, Asante Akim North and South, Obuasi, Bosomtwe and Amansie Central District Assemblies during the tenure of H. E. John Agyekum Kufuor, former President of Ghana (November, 2008 – January, 2009). Work Experience His major landmark business establishment is Silkcoat Company GH LTD – corporate dealership in quality paints and local representatives of Silk-Coat International in Turkey and Amaant Prestige Co. Ltd, a consortium that provides consultancy services and quality control in diverse areas of national development. He was the Executive Director of Amaant Prestige Company Limited from 2010 to 2017 Antwi did some stints with the then Internal Revenue Service as an Inspector of Taxes and Abura Printing Press (Publishers of Pioneer Newspaper) as an Assistant Accountant between 1987 and 1988. Before becoming the General Manager of Freko FD Limited Managers of the Kejetia Terminal between 2001 and 2004. 36

With this mix of experience and professional exploits and remarkable development traits associated with his leadership, his assumption of the office of the Metropolitan Chief Executive of the Kumasi Metropolitan Assembly is seen as historic and a welcome opportunity to make a difference in the development of Kumasi and Ashanti Region as a whole.

Martine Bellanger PhD Professor of Health Economics EHESP School of Public Health France

Martine M Bellanger is professor of Health Economics at the EHESP School of Public health in Paris, France. She is also director of the Master of Public Health (MPH). Previously, she taught micro-economics and mathematics for economics at the University of Nantes, in which she wrote her PhD on decision theory and elderly policies in France. Her main interests for both research and teaching are in economic analysis of health care and economic evaluation. Currently, her particular focus is comparative analysis addressing questions related to evaluation of public health prevention programmes and new technologies. Measuring efficiency in health care is becoming a growing research interest, with a particular attention to services for patients with chronic diseases such as Alzheimer diseases and cancer. She has also contributed to research focusing on economic saving associated with the reduction of children exposures to lead, mercury and endocrine disrupting chemicals (EDC) not only at the French and the European levels, but also at the global level for environmental exposures. Last she has been co-chair of the international symposium on breast cancer prevention since 2011.

Angela Bradbury MD Division of Hematology-Oncology, Department of Medicine The University of Pennsylvania Pennsylvania, USA Angela Bradbury completed her residency in internal medicine at the University of Chicago, where she later completed two fellowships (one in hematology/oncology and one in medical ethics). She is currently an Associate Professor in the Department of Medicine, Division of Hematology-Oncology, at the University of Pennsylvania and also has a secondary appointment in the Department of Medical Ethics and Health Policy. She is also the founder and Executive Director of the Penn Telegenetics Program, a national program offering remote genetic services to medical practices without access to genetic providers. Dr. Bradbury specializes in the treatment of breast cancer and cancer genetics. Her research program focuses on the clinical implementation of genetic medicine to promote the health of individuals and families. This includes research evaluating novel delivery models to facilitate dissemination and implementation of cancer genetics and evaluation of the psychosocial and behavioral outcomes of genetic testing, studies evaluating outcomes with return of genetic research results and the impact of genetic and familial risk on children, adolescents, and families.

Marissa Burgermaster PhD Assistant Professor of Nutritional Sciences and Population Health University of Texas at Austin Texas, USA Marissa Burgermaster is an assistant professor at University of Texas at Austin. She is joint appointed to the faculties of Nutritional Sciences in the College of Natural Science and Population Health at Dell Medical School. Her research applies data science and humancomputer interaction methods to improve nutrition and community health. Prior to joining UT, Dr. Burgermaster completed a postdoctoral fellowship in biomedical informatics at Columbia University Irving Medical Center where she conducted research on technologies for diabetes management among underserved New Yorkers. She was granted an early career award from the Sackler Institute for Nutrition Science at the New York Academy of Sciences to support her work developing methods for psychosocial phenotyping. She was also the behavioral nutrition lead for the CUIMC-based team that developed “Taming Type 2 Diabetes Together (T2D2),” a voice application for personalized nutrition and diabetes selfmanagement that was a finalist in the 2017 Alexa Diabetes Challenge and the 2017 World Cup of Voice Tech in Diabetes. Dr. Burgermaster holds a PhD in Behavioral Nutrition from Columbia University, where her research at Teachers College’s Tisch Center for Food, Education, & Policy focused on improving the evaluation of school-based childhood obesity prevention interventions. Dr. Burgermaster holds an MS in Nutrition and Food Science from Montclair State University and an MAEd in Curriculum and Instruction from William & Mary. She previously had a career as a teacher and school administrator.

Pierre-François Cartron PhD Institut de Cancérologie de l’ouest France Pierre-Francois Cartron obtained his Ph.D in molecular biology from "Ecole Pratique des Hautes Etudes Paris La Sorbonne" in 2004 (jan), then embarked on a post-doctoral fellowship to Memorial Sloan Kettering Cancer Center (Dr EC Holland’s lab, New York). Since 2005 (nov), PFC works at INSERM (France). PFC's lab focuses its researches on the link between epigenetic and apoptosis and immune escapes in cancer cells. By dissecting molecular mechanisms of epigenetics, PFC' lab aims to develop innovative biomarkers and epidrugs in order to use it in personalized medicine against cancer. Since 2014, PFC also works at Institut de Cancérologie de l'Ouest (ICO, Saint-Herblain, France). PFC is also the scientific coordinator of two French epigenetic networks (REpiCGO and EpiSAVMEN) focused on the study of relationship existing between epigenetic, cancer initiation and progression, drugs resistance, and pollutant).

Luis G. Carvajal-Carmona PhD, Associate Professor Department of Biochemistry and Molecular Medicine, School of Medicine University of California Davis California, USA Luis Carvajal-Carmona, is an Associate Professor at School of Medicine of the University of California, Davis (UC Davis) and the Co-Leader of the Population Sciences and Health Disparities Research Program at the UC Davis Comprehensive Cancer Center. He specializes on cancer genetics, epidemiology and health disparities. He obtained his Ph.D. from University College London (UK), carried out postdoctoral training at the Cancer Research UK London Research Institute (now part of The Francis Crick Institute) and was a Senior Research Fellow at the University of Oxford before taking his faculty position at UC Davis in 2012. Dr. Carvajal-Carmona has received funding from multiple agencies in Europe (Cancer Research UK, European Union, GSK Oncology) and the U.S. (V Foundation, NIH) and is currently Principal Investigator in three National Cancer Institute grants. Currently, Dr. Carvajal-Carmona is a member of the CHSA Study Section, a member of the Minorities in Cancer Research Council at the AACR, a UC Davis School of Medicine Deanâ&#x20AC;&#x2122;s Fellow in Precision Medicine, the Associate Director of UC Davis T32 Biotechnology Training Program and the Co-Chair of inherited susceptibility group within the University of California Pancreas Cancer Consortium. Dr. Carvajal-Carmona has discovered several cancer susceptibility genes and has published over 80 publications in influential journals such as Nature Genetics, Gastroenterology, American Journal of Human Genetics and PNAS. His has received awards and fellowships from the European Association for Cancer Research, The University of Oxford and the V Foundation. In addition to his passionate pursuit for scientific research, Dr. Carvajal-Carmona is a keen supporter of a diverse biomedical research force and has mentored several first-generation students and members of under-represented groups in biomedical research.

Marisa Fazzino

MD Medical Oncologist Director of Oncology Department Hospital Policial Montevideo, Uruguay Fazzino received her medical degree in 1989 and Oncology degree in 1994 from the University of the Republic (UDELAR) in Montevideo, Uruguay. She received a Masters in Mastology (Uruguayan Societies of Mastology and Gynecology in 1993-1994, and also a scholarship in oncology at the National Cancer Institute of Milan, Italy in 1997-98. She has been an oncology consultant at the National Program for Prevention of Cervical Cancer and at the Honorary Commission for the Fight Against Cancer until 2012. Currently Fazzino is Director of the Oncology Department at the â&#x20AC;&#x153;Hospital Policialâ&#x20AC;? and President of the Committee of Continuous Medical Education of the Medical and Pediatric Oncology Society of Uruguay. She has participated in Symposiums, Congresses in Latin America, Europe and the United States of America and she has been principal Investigator and co-investigator in multicenter clinical trials. During her career, she has been President of the Medical and Pediatric Oncology Society of Uruguay and she has been member of Board of National and International Societies of Mastology and Oncology.

Andreas H Hielscher PhD, Professor of Biomedical Engineering, Radiology (Physics) and Electrical Engineering, Columbia University New York, USA Andreas H. Hielscher received his PhD degree in Electrical and Computer Engineering from Rice University, Houston, Texas, in 1995. After spending 2 years as Postdoctoral Fellow at the Los Alamos National Laboratory in New Mexico, he joined the faculty at the State University of New York Downstate Medical Center in Brooklyn, New York. In 2001 he moved to Columbia University in New York City, where he is now the Director of the Biophotonics and Optical Radiology Laboratory. He holds appointments as Full Professor in the Departments of Biomedical Engineering, Electrical Engineering and Radiology, and served as Chair of the Department of Biomedical Engineering from 2011 to 2013. Hielscherâ&#x20AC;&#x2122;s work focuses on the development of state-of-the-art systems for optical tomography. He applies this emerging medical imaging technology to diagnose and monitor arthritis, vascular diseases, breast cancer and early childhood cancer. He has published over 250 scientific articles and conference proceedings, which have been cited over to 8000 times. Hielscherâ&#x20AC;&#x2122;s work has been funded, among others, by the National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Institutes of Biomedical Imaging and Bioengineering (NIBIB), National Heart, Lung, and Blood Institute (NHLBI), the National Cancer Institute (NCI). In addition, he has organized numerous conferences and was the General Chair for the 2015 European Conference on Biomedical Optics. He is an elected Fellow of the American Institute for Medical and Biological Engineering (AIMBE) and regularly serves on review panels for the NIH, NSF, and international science funding organizations, such as the British Welcome Trust, and the German Research Foundation (DFG).

Lauren Houghton PhD Columbia University New York, USA

Lauren C. Houghton, takes a biocultural approach to breast cancer prevention. Using tools from molecular epidemiology, she examines the steroid metabolome in relation to intermediate outcomes, including pubertal development and the menstrual cycle, and breast cancer risk. Having a background in anthropology, Houghton is also interested in developing mixed-methods to better capture biological and cultural mediators of womenâ&#x20AC;&#x2122;s health disparities and to use digital health platforms in the dissemination and implementation of the latest menstrual and breast cancer science.

Charlotte Huet MD, PhD Centre EugĂ¨ne Marquis Rennes, France

Huet is a public health physician graduated at the Medical University Victor Segalen of Bordeaux, in which she wrote her PhD on the use of technologies to minimize allogeneic blood transfusion within a research international collaboration from ten countries.

Huet has worked in sub-Saharan Africa for the French Ministry of Foreign Affairs as an epidemiologist within a clinical research programme on prevention and care management of HIV infection focusing first on blood donors in Abidjan (Ivory Coast) during five years (20002005) and then on female sex workers in Bobo-Dioulasso (Burkina Faso) for four years (20062010).

Currently, she is the medical coordinator of the Phare Grand Ouest project, a program for the health care management of patients with genetic predisposition to cancer, involving four regions in Western France. This initiative started in late 2010 funded by the National French Cancer Institute and is particularly focused on women at high risk for breast cancer, with or without BRCA1/2 mutations.

Nahla Hwalla PhD, RD, FAND Professor of Human Nutrition Faculty of Agricultural & Food Sciences American University of Beirut Beirut, Lebanon

Nahla Hwalla is Professor of Human Nutrition and Registered Dietitian with the Academy of Nutrition and Dietetics, USA. Her research focuses on obesity, its prevalence, determinants and dietary manipulation to curb its effects. She has published over 100 seminal articles on obesity, nutrition and diet-related diseases in high-impact peer-reviewed international journals. More recently, she expanded her research to the importance of diets in tackling the Sustainable Development Goals and food and nutrition insecurity. She has received extensive funding for her research from local and international agencies such as WHO, IAEA and the Lebanese National Council for Scientific Research (CNRS). Hwalla has provided Lebanon with the 1st and 2nd national studies on obesity and has established an Associated Research Unit on Under-nutrition and Obesity and another on Nutrition and Non-communicable Disease supported by the Lebanese CNRS. She has established the 1st academic program in Nutrition and Dietetics in the country and the region, and has devoted her career life to establishing Dietetics as a highly recognized and respected profession. She established the 1st NGO for nutritionists in Lebanon and the region, the Lebanese Academy for Nutrition and Dietetics (LAND). In recognition, elected as Fellow of International Union of Nutritional Sciences (IUNS) in 2009, being the first 1st IUNS member from the Middle East to receive this recognition, and Fellow of the Academy of Nutrition and Dietetics (FAND) in 2014. Recipient of the 2012 Distinguished Researcher Award by the Lebanese CNRS, the 2014 Susan Bulkely Butler Leadership Excellence Award by the International Breast Cancer and Nutrition (IBCN) group at Purdue University, USA, and recently of the Researcher Pioneer Award by the Lebanese parliament. Elected, more recently, as Chair of CIHEAM Advisory Board. Received Takreem regional award 2017 for Excellence in education .

Marion Lee

PhD The Center for Health and Community University of California San Francisco, USA and Institute of Epidemiology and Preventive Medicine National Taiwan University Taipei City, Taiwan Marion M. Lee is Professor Emeritus of Epidemiology at the School of Medicine, University of California, San Francisco; a Consulting Professor at Stanford University, School of Medicine; a Visiting Professor of Preventive Medicine at College of Public Health, National Taiwan University, Taiwan. Lee received a masterâ&#x20AC;&#x2122;s degree in public health from Yale University, a PhD in epidemiology from UC Berkeley and completed the post-doctoral training at Stanford University. Lee has taught clinical research method, nutritional epidemiology and preventive medicine for over 30 years both in the United States and in Asia. Her research focuses primarily on cancer, nutrition and aging with special interest on Traditional Chinese Medicine and integrative medicine. Dr. Lee has served on study sections at National Cancer Institute, and on International research grant review committees; she also has served as research council at Taiwan National Health Research Institute for many years. More recently, Dr. Lee serves as cancer research grant reviewer for Ministry of Health and Welfare in Taiwan. In her spare time, Lee has published many books for the general public including three books about breast cancer in Chinese language as well as a bilingual book on breast cancer recovery and healing.

Sophie Lelièvre

PhD, DVM, LLMPH Professor of Basic Medical Sciences with courtesy appointment in Nutrition Science; coleader, Drug Discovery & Molecular Sensing NCI-designated Purdue Center for Cancer Research; Scientific Director, 3D Cell Culture Core (3D3C) Facility, Birck Nanotechnology Center, Discovery Park Purdue University Indiana, USA Lelièvre is a native of France who obtained her undergraduate degree as Engineer in Veterinary Sciences from the University of Louvain (Belgium) and her D.V.M. degree from the University of Liège (Belgium) in 1990. She worked as a veterinarian in the emergency room in Paris area (France) from 1990 to 1995, while pursuing M.S. and Ph.D. graduate studies in Cancer Pharmacology at the Gustave Roussy Cancer Institute and University of Paris VI (Pierre & Marie Curie). Dr. Lelièvre is the 1995 recipient of (i) the National Prize for Fundamental Cancer Research/young investigator from the French Society of Cancer and National Federation of Cancer Institutes and (ii) the National Alexandre Joel Prize for young investigator from the Association for Cancer Research. During her postdoctoral training in Mina Bissell’s laboratory at the Lawrence Berkeley National Laboratory (USA) from 1995 to 2000, she studied the role of the organization of the cell nucleus in normal and cancerous breast epithelial cell behaviors using three-dimensional models of cell culture that recapitulate aspects of tissue organization in vivo. Lelièvre joined the Department of Basic Medical Sciences at Purdue, as a faculty member and Walther Cancer Institute Scholar, in October 2000. Her research program has been externally funded by the National Institutes of Health, the Department of Defense-Congressionally Directed Medical Research Programs (CDMRP) among other agencies. It focuses on the role of the organization of the cell nucleus in gene expression and genome stability and the relationship between tissue polarity and nuclear functions, notably epigenetic control. Translational projects are targeted towards prevention of breast cancer onset and progression. She was one of the three featured breast cancer researchers of the CDMRP in 2008 in recognition for her contributions to breast cancer research since her early career development funding by CDMRP in 1997. Her research accomplishments include notably, (i) the development of methods to analyze and detect phenotypes based on cell nucleus organization at the single cell level, (ii) the design of preclinical three-dimensional (3D) cell culture models including organs-on-a-chip to be used for screening protective agents against breast cancer development and for the design of nanomedical tools for therapies, and (iii) the identification of early breast tissue alterations necessary for cancer development and related new potential targets for breast cancer prevention and treatment. In 2015, she created the 3D Cell Culture Core (3D3C) Facility at Purdue University with the aim of bringing engineers and biologists together to design better models for research on chronic diseases. For her work with organs-on-a-chip she was selected for the Innovator Hall of Fame of Purdue Research Foundation. She was also appointed as advisory board member for 49

the new journal “Microphysiological Systems” (Eds. Zhang, Harvard Med. School and Huh, U. Penn). To better integrate public health related disciplines to her research projects, Lelièvre completed a Master’s degree in Law, Health and Ethics from a EuroPubhealth and Erasmus Mundus international program in 2008 at the University of Rennes (France). She initiated an international and multidisciplinary program on primary prevention of breast cancer (www.purdue.edu/IBCN) in 2009 that has received logistic support from the World Health Organization and includes 15 partner countries and yearly symposia (www.purdue.edu/breastcancer). Lelièvre was selected as a Purdue Entrepreneurial Leadership Academy Fellow in 2009 and Scholar in 2010 and as the 2012 Discovery Learning Research Center Faculty Research Fellow to pursue aspects of this international program. For her work on cancer prevention, she received an Indiana Women of Achievement Award in 2015. She is also a Purdue University Faculty Scholar and was an appointed member (2011-17) of the NIH, NCI-I study section for K awards supporting the training of scientists toward independence in research. Lelièvre teaches Applied Pharmacology in the Purdue DVM program. She is developing a distance learning course on International Primary Prevention Research for chronic disease at Purdue University and has been a recurring invited lecturer on cancer prevention in the international Master of Public Health of the School of Public Health in France.

Jasmine McDonald ScD, Assistant Professor Department of Epidemiology Columbia University New York, USA McDonald received her PhD in Biological Sciences in Public Health in 2009 from Harvard University. She received her B.S. in Biochemistry/Molecular Biology from the University of Maryland, Baltimore County in 2003 where she was a Meyerhoff and MARC U*STAR Scholar. McDonald is an Assistant Professor of Epidemiology at the Mailman School of Public Health (MSPH) at Columbia University as well as the co-Director of the Herbert Irving Comprehensive Cancer Center (HICCC) Continuing Umbrella of Research Experience (CURE) Program. Upon completion of her doctoral degree, McDonald sought to cultivate a multidisciplinary frame of public health research focused on high cancer risk populations. She completed a postdoctoral fellowship at the University of Pennsylvania and at Mailman, where she focused on sociobehavioral factors and environmental exposures within populations with high breast cancer risk. As an Assistant Professor of Epidemiology at Mailman, McDonaldâ&#x20AC;&#x2122;s research portfolio focuses on key windows across the lifecourse where the breast tissue may be more vulnerable to environmental exposures; such as during the pubertal and postpartum periods of breast development. She has a K01 from the National Cancer Institute (NCI) to examine the role of childhood infections on pubertal timing in girls. She is also funded through NCI to examine structural and physiological changes in the breast microenvironment in postpartum women. Given McDonaldâ&#x20AC;&#x2122;s doctoral training in basic sciences and her postdoctoral experiences in Cancer Epidemiology in high-risk populations, her research portfolio incorporates molecular epidemiology tools to elucidate etiological causes and biological mechanisms of breast cancer prevention in young women.

Rihab Nasr

PhD Associate Professor Department of Anatomy, Cell Biology and Physiological Sciences Director of Basic Research Core Facilities Director of Cancer Prevention and Control Program Founder and Director of AMALOUNA American University of Beirut Beirut, Lebanon Rihab Nasr is an Associate Professor in the department of Anatomy, Cell Biology and Physiology, the director of the Basic Research Core Facilities and the director of Cancer Prevention and Control Program at the Faculty of Medicine at the American University of Beirut. Nasr received her PhD in Fundamental basis of oncogenesis from the University of Paris VII in France. Her major research activities focus on cancer biology and therapeutics. Specifically, she is interested in developing targeted therapies for human leukemias as well as in epigenetics modifications including microRNAs and their implication in cancer. Overall, her work led to the publication of highly cited original articles in leading scientific journals including Nature medicine, Cancer Cell, Blood, Scientific Reports and International Journal of Cancer. Nasr received the Best Biomedical research award from Qatar Foundation in 2011, was selected as one of the seven top Arab Women by Sayidati magazine for the year 2013, was the recipient of UNESCO L’Oreal “For women in Science” Levant and Egypt fellowship in 2014, the Arab American frontiers fellowship in 2014, 2016 and 2017 as well as the Franco-Lebanese Scientific Excellence award by the Legion of Honor in Lebanon and the French Institute in 2015. Nasr is the founder and director of AMALOUNA, an AUB affiliated educational organization whose mission is to fight cancer through focusing on three pillars: education, research and prevention.

Song-Yi Park PhD Associate Specialist, Cancer Epidemiology Program University of Hawaii Cancer Center Hawaii, USA

Park earned a B.S., a M.S., and a Ph.D. degrees all in food and nutrition from Seoul National University in Seoul, Korea (1992-2002). During her graduate work, Park was a research assistant for several community-based nutrition research. Her master thesis work entitled "Frequently consumed dished and their recipes in Korean rural area" was a part of the research project to develop a dietary assessment software for rural people. Her doctoral dissertation work was on the dietary acculturation of an ethnic minority in the US, entitled "A study on the comparison of diet in Korean American and Korean families with adolescents." After completing her Ph.D. degree, Park worked as an Executive Director of the Korean Home Economics Association in Seoul, Korea, which is publishing two periodic journals and is organizing nationwide conferences twice per year. Park moved to Hawaii in 2004 for postdoctoral training in Cancer Epidemiology Program at University of Hawaii Cancer Center (UHCC), with a postdoctoral fellowship grant awarded from the Korean Science & Engineering Foundation. Since then, her research in cancer epidemiology has been focusing primarily on individual dietary components and overall dietary patterns and their relationships to cancer risk and secondly on other lifestyle factors including obesity and physical activity. Park has analyzed data from the Multiethnic Cohort Study (MEC), which is a National Cancer Institute (NCI)-funded, population-based cohort study of diet and cancer, established in 1993-1996. The MEC consists of more than 215,000 participants who are mostly African American, Native Hawaiian, Japanese American, Latino, and white living in Hawaii and California. She has investigated the associations of diet and other lifestyle factors with risk of common cancers including breast, prostate, and colorectum, and whether the associations varied by race/ethnicity. Park has continued her research in the MEC as a Co-Investigator since 2009 when she was appointed as a faculty member, Assistant Specialist, of the UHCC. She has also worked as a CoInvestigator of the African American Breast Cancer Epidemiology and Risk (AMBER) Consortium, funded by NCI. The AMBER Consortium comprised the MEC and three other US cohorts. Dr. Park has been recently promoted to an Associate Specialist. She is a member of American Society for Nutrition and Society for Epidemiologic Research. She is the author of over 55 peerreviewed articles including 14 papers about breast cancer studies and 6 book chapters.

Rahim Rahimi PhD Assistant Professor, Materials Engineering Purdue University Indiana, USA Rahim Rahimi is an Assistant Professor in the Materials Engineering department at Purdue University. He earned his B.S. (2009) and M.S. (2012) degrees in Electrical Engineering from the Iran University of Science and Technology, and his Ph.D. (2017) degree and post-doctoral (2018) in Electrical and Computer Engineering from the Purdue University, USA. His research has explored development of innovative, scalable, multifunctional, microsystem platforms for medical applications, with emphasis on smart wearable and autonomous devices for wound monitoring and therapy. His research on smart dressing for burn victims and stretchable embroidered electronics has been featured in various news media, including Science Nation, Science360, The Computer World, and Science X. During his graduate and post-graduate career, he has co-authored over 50 publications in world renowned journals and international conferences as well as book chapter and patents. Rahimi has also has led research teams on multi-institutional research endeavors focused on developing scalable manufacturing processes of flexible electronic devices that can empower technologies for healthcare and environmental monitoring.

Leslie Reinlib PhD Breast Cancer & the Environment Research Program National Institute of Environmental Health Science Washington, DC; USA

Les Reinlib is a Health Scientist Administrator at the National Institute of Environmental Health Sciences, NIH. He is the founding Director and program team for the Breast Cancer and the Environment Research Program, a national study that is a first step into understanding the impact of exposures at specific life points - such as puberty and pregnancy - on the predisposition for breast cancer. Reinlib develops and administers scientific programs in molecular and experimental carcinogenesis, genomic integrity, and leads efforts in stem cell and developmental biology. As part of the ongoing efforts, he works with community outreach specialists to promote bidirectional conversations with target communities on their health and environmental concerns and has a proud association with advocates for breast cancer research and prevention.

Reinlib received a BS and MS in Biology from the University at Albany and a Doctorate in Natural Sciences and Biochemistry from the Swiss Federal Institute of Technology in Zurich, Switzerland. He was on the faculty of Tufts University â&#x20AC;&#x201C; New England Medical Center and later the Johns Hopkins University School of Medicine before joining the NIH in 1990. Throughout his career, Reinlib has worked with laboratory and clinical investigators focusing on cellular mechanisms of disease. He has published reports on stem cell biology and therapy, genome integrity, environmental origins of lupus, mechanisms of heart failure, and second messenger regulation underlying health disorders.

Sharon Ross

PhD, MPH Program Director, Nutritional Science Research Group, Division of Cancer Prevention National Cancer Institute, National Institutes of Health USA Ross was born in Connecticut and lived much of her early life in New England. She obtained her undergraduate degree at the University of New Hampshire in Nutrition and Dietetics. Soon thereafter she received a Master of Science degree in Nutritional Sciences from the University of Connecticut. At UConn she adapted the micro-Kjeldahl apparatus and procedure for the analysis of human milk for her thesis work entitled, â&#x20AC;&#x153;Nitrogen distribution in mature human milk.â&#x20AC;? After completing her thesis work, Ross was a research assistant at the United States Department of Agriculture, Human Nutrition Research Center on Aging at Tufts in Boston where, among other responsibilities, she performed amino acid analysis of biological specimens using a dedicated high-performance liquid chromatography system. Thereafter she held a senior research technician position in the Department of Nutrition and International Health, Boston University School of Medicine studying the effects of dietary phospholipid intake on phagocytosis function of human polymorphonuclear neutrophils. Ross received a University of Maryland, Graduate School Fellowship in 1987, and from 1990 to 1993 she was a Pre-Doctoral Intramural Research Training Fellow in the Laboratory of Cellular Carcinogenesis and Tumor Promotion, Division of Cancer Etiology, National Cancer Institute (NCI). Her dissertation research, performed at NCI, was under the mentorship of Luigi De Luca. This research primarily concerned the role of retinoids in growth, differentiation, and cell adhesion of human neuroblastoma and mouse teratocarcinoma cells. Ross received her PhD in Nutritional Sciences from the University of Maryland in 1992. Her Postdoctoral position was as a NCI Cancer Prevention Fellow and as part of the fellowship program she received a Master of Public Health degree from Johns Hopkins University School of Public Health with an emphasis in Epidemiology. Thereafter, Ross was a Senior Staff Fellow at Center for Food Safety and Applied Nutrition, Food and Drug Administration (FDA). Soon she became a federal employee as a Nutritionist at FDA whose responsibilities included reviewing, evaluating, and summarizing scientific evidence for substance/disease relationships relative to dietary supplements and foods that were submitted by outside organizations in support of health claim petitions. Ross joined the Nutritional Sciences Research Group, Division of Cancer Prevention at NCI in 2000. In this capacity, she has more than 18 years of experience in directing, coordinating and managing a multi-disciplinary research grant portfolio in diet, nutrition, and cancer prevention. Topics in her portfolio and research interests include: nutrition and gene regulation/epigenetics and cancer prevention; mechanisms linking diet, obesity and cancer; relationships between diet 56

and microbiota during carcinogenesis; as well as discovery of nutrient action through emerging technologies. A more recent research interest involves the relationship between nutrition and microRNA expression and function as well as the influence of extracellular vesicles and their cargo on nutrient metabolism. Ross received an NIH Individual Merit Award 2009 for her â&#x20AC;&#x153;leadership in forging a greater understanding of the role of bioactive food components as significant modifiers of epigenetics.â&#x20AC;? She is the recipient of the 2009 American Society for Nutrition Norman Kretchmer Memorial Award in Nutrition and Development. Ross has been on the Journal of Nutrition Editorial Board since 2008.

Graciela Sabini MD Ministry of Health Montevideo, Uruguay Sabini was born in Montevideo (Uruguay). She is a Medical Doctor, specializing in Medical Oncology. She had fellowships of specialization in Centre LĂŠon BĂŠrard (Lyon, France, 1978 and 1986) and NCI (USA) (1984) in the area of Hormone Receptors and Cancer. For over 35 years, Sabini worked in the Faculty of Medicine of the Republic University. Her last position was Professor of Clinical Oncology. She has been dedicated to education in all her positions. She was Director of the National Cancer Control Program (Ministry of Health) and Coordinator of the Technical and Professional Training Area of the Honorary Committee to Fight Against Cancer. She has won international scholarships. She received the First National Prize of Medicine and two National Prizes of Medicine. Honorable mentions. She has participated in many national and international scientific activities with over one hundred lectures and has published more than 100 scientific articles. Sabini has participated in the creation of Mastology Units and Palliative Care Units. Although currently retired from clinical activity, she is invited to the scientific activities on cancer and chronic diseases that are performed in the country as a referent.

Victoria Seewaldt MD, PhD Ruth Ziegler Professor and Chair of the Department of Population Science Associate Cancer Center Director City of Hope California, USA Victoria L. Seewaldt, M.D., is the Ruth Ziegler Professor and Chair of the Department of Population Science at City of Hope and Associate Cancer Center Director. Seewaldt was born in New York City to a Slovak immigrant family and is proud to be part of the diversity that defines the American experience. Seewaldt received her undergraduate degree in chemistry from Cornell University and attended medical school at University of California at Davis. She trained in OB/Gyn (internship), Internal Medicine (residency), and Medical Oncology (fellowship) at University of Washington and Fred Hutchinson Cancer Research Center. From 2000-2015, Seewaldt was a Professor at Duke University where she led a research program that made discoveries in the laboratory and then used these findings to develop trials clinical trials to improve early detection and prevention of biologically aggressive breast cancer. Seewaldt returned to California in 2015 to lead a research program and the Department of Population Science at City of Hope. Her goal is to continue to improve early detection of aggressive cancers. She also works to serve the Los Angeles community, through mentorship, education, and teaching. Seewaldt believes that womenâ&#x20AC;&#x2122;s care means respecting the whole woman -- her community, beliefs, preferences, and body. Seewaldt addresses issues that include breast cancer prevention strategies, discussion of surgical and screening options for high-risk women, menopause, diabetes prevention, and reestablishing sexual relationships after cancer treatment. Clinically, Seewaldt aims to empower women who are at risk for breast cancer and be full partners in developing wellness strategies that promote full person health and access to cutting-edge clinical trials.

Sudha Sivaram DrPH, MPH Chief of the Public Health, Networks and research branch Center for Global Health, National Cancer Institute, National Institutes of Health Maryland, USA

Sudha Sivaram is Chief of the Public Health, Networks and research branch at the Center for Global Health at the US National Cancer Institute (NCI). In this capacity, she works with colleagues across the institute to develop and coordinate research funding programs in global cancer control and enhance training programs in cancer research. She serves in peer review committees for the US Centers for Disease Control grant funding program as well the US Centers for Medicare and Medicaid. Sivaram is a member of several trans-NCI and National Institute of Health committees that coordinate biomedical research, specifically focusing on topics such as Dissemination and Implementation, Cancer Health Disparities, and Bioethics. She serves on the Joe Biden Cancer Moonshot Implementation Team focused on Patient Engagement in Cancer Research. She also is a steering committee member for the International Cancer Screening Network as well as NIH-funded GeoHealth research program. Finally, Sivaram helps coordinate cooperation in cancer research and training in the South Asia region.

Sivaram is trained in epidemiology and social science and her interests are to help bring public health research data and evidence to practice. She has worked extensively in the South Asia region in implementation science research. She focuses on the role of structural and environmental factors such as the role of access and use of technology, breakdown in process of care for cancer prevention and treatment, and the role of health systems factors in influencing cancer prevention knowledge and behaviors. In addition to her work for the US Government, Sivaram is also an associate faculty at the Johns Hopkins University Bloomberg School of Public Health where she is involved in teaching and working on global health programs and where she was faculty in epidemiology prior to her federal tenure.

Rabih Talhouk PhD Professor, Biology Department & Chairperson University Graduate Council American University of Beirut Beirut, Lebanon Rabih Talhouk, Professor of Cell Biology and Chairperson of the recently established Graduate Council at the American University of Beirut (AUB), obtained his PhD in 1988 at Ohio State University. He then held a joint post-doctoral position at the Lawrence Berkeley National Laboratory and University of California San Francisco before joining the Biology Department at AUB in October 1992. He has been there since. With more than 75 publications, current work in his laboratory focuses on two main lines of research. The first has to do with deciphering the mechanisms that regulate the interaction of the cell with its microenvironment. Namely; the role of the transmembrane gap junction proteins, connexins, and their associated proteins, catenins and zonula ahderens, in mammary epithelial cell (MEC) differentiation and transformation in two dimensional (2D) and three dimensional (3D) cell culture models. The second line of research aims at identifying bioactive molecules with anti-inflammatory and anticancer properties in extracts of indigenous medicinal flora and marine fauna. For that 2D and 3D culture models are used to decipher their mechanisms of action. Talhouk has mentored more than 55 graduate students since he joined AUB who went on to pursue research and doctoral studies in prestigious universities abroad. In 2010 he won the AUB teaching excellence award and in 2018 the Lebanese Industrial Research Achievement (LIRA) Distinguished Supervisor Award. He has been involved in campus wide strategic planning, and university accreditation. Talhouk has also served AUB as Chairperson of the Biology Department and founding Chairperson of the University Graduate Council, and has held leadership positions on several university committees. He co-authored the government adopted biology text-book for grade 12 in all schools of Lebanon. He is also a founding member of AUBâ&#x20AC;&#x2122;s interdisciplinary Nature Conservation Center, and a founding board member of the Society for Advancement of Science and Technology in the Arab World (SASTA), a USA-based NGO. He has held several consultancies on adoption of biotechnology in the MENA region, food security, GMO and biosafety. He also served on consulting teams to Universities in the Gulf region.

Andy Tao PhD Professor Department of Medicinal Chemistry & Molecular Pharmacology and Department of Chemistry Purdue University Indiana, USA W. Andy Tao received his Ph.D. from Purdue University in 2001, under the supervision of Prof. R. Graham Cooks. After a postdoc with Drs. Leory Hood and Ruedi Aebersold at Institute for Systems Biology, Seattle, W. Andy Tao joined the Department of Biochemistry in 2005 and was promoted to rank of Professor in 2014.

Current research in the lab of W. Andy Tao lab focuses on developing novel chemistry to solve important biological questions, with a special emphasis on characterizing proteins involved in signaling transduction and diseases using state-of-the-art analytical tools.

Tao holds courtesy appointments at the Department of Medicinal Chemistry & Molecular Pharmacology and Department of Chemistry, Purdue University, and has also been adjunct Professor in the Center for Plant Stress Biology, Chinese Academy of Science and Southeast University in China. He is an active member in Purdue University Center for Cancer Research.

He has won multiple awards, including Damon Runyon Fellowship (2003-2005), American Society for Mass Spectrometry (ASMS) Research award (2006), NSF-Career Award (2007-2012), and Purdue Faculty Outstanding Commercialization Award (2017).

He is an elected Board member (2017-2020), US Human Proteome Organization (HuPO) and President (2017-2019), Chinese American Society for Mass Spectrometry (CASMS). He has served on multiple committees, including ASMS Education Committee (2010-2012), ASMS graduate award committee (2017-2019), HUPO Awards Nomination Committee (2018-2020).

Parisa Tehranifar DrPH Columbia University Mailman School of Public Health New York, USA Parisa Tehranifar, DrPH focuses her research on cancer health disparities and breast cancer prevention. One area of her work focuses on understanding the contribution of emerging medical interventions as a source of health disparities, and includes an ongoing study that examines the role of mammographic breast density disclosure in relation to breast cancer screening disparities. She also leads studies of determinants and distribution of mammographic density in women of racially/ethnically diverse and predominantly immigrant backgrounds, and on integration of mammographic density in clinical risk assessment in women with family history of breast cancer.

Mary Beth Terry PhD Professor of Epidemiology Environmental Health Sciences Columbia University New York, USA Mary Beth Terry, PhD, focuses her research on breast cancer and in the molecular epidemiology and lifecourse methods of the disease, in particular. She is a cancer epidemiologist with over 18 years of leading studies of breast cancer etiology specifically focused on the role of genetics, epigenetics, and other biomarkers play in modifying the effects of environmental exposures. Terry currently leads NIH grants funded through the National Cancer Institute and the National Institute for Environmental Health Sciences that focus on following cancer risk within familybased cohorts focused on studying environmental exposures during key windows of breast susceptibility. She is also leading prospective studies to validate and extend breast cancer risk assessment models. She is also funded through the Breast Cancer Research Foundation. Her more recent work supports that environmental exposures and biomarkers are associated with modifying risk even within high risk families. Understanding whether biomarkers can help explain risk in higher risk women is important as only a minority of women with a family history of cancer carry the BRCA1 or BRCA2 mutation. Her work also focuses on measuring risk factors for mammographic density, a strong intermediate marker of breast cancer. In addition to her doctorate in epidemiology, Terry has a Master's degree in economics and previously worked as an econometrician and program evaluator for a number of government-sponsored programs. Terry teaches introductory and advanced epidemiologic methods.

Pierre-Alexandre Vidi PhD Assistant Professor Cancer Biology Wake Forest University North Carolina, USA Pierre Vidi is an Assistant Professor of Cancer Biology at the Wake Forest School of Medicine, and a member of the Comprehensive Cancer Center of Wake Forest University. Vidi is a cell biologist who received his Ph.D. from the University of NeuchĂ˘tel (Switzerland) in 2006 and trained as a postdoctoral fellow at Purdue University. Research in his laboratory is centered on cancer prevention and focuses on the role of tissue architecture and nuclear organization during the early steps of cancer initiation.

Connie Weaver PhD Nutrition Science Purdue University Indiana, USA

Connie M. Weaver, Ph.D., is a Distinguished Professor at Purdue University in the Department of Nutrition Science in West Lafayette, Indiana. She is an elected member of The National Academies of Science, Engineering, and Medicine since 2010 and a member of the Food and Nutrition Board. She is a member of the FDA Science Advisory Board and the NIH Advisory Committee on Research on Women’s Health. She is founder and director of the Women's Global Health Institute (WGHI) at Purdue University. The mission of the WGHI is to improve the health of women globally through research and training by proactively identifying the causes and prevention of diseases related to women. She is Deputy Director of the National Institutes of Health funded Indiana Clinical and Translational Science Institute since 2008. Her research interests include mineral bioavailability, calcium metabolism, and bone and cardiovascular health. Dr. Weaver is past-president of American Society for Nutritional Sciences (ASN). She is on the Board of Trustees of the International Life Sciences Institute, Showalter Biomedical Research Committee, and the Science Advisory Board of Pharmavite. For her contributions in teaching, Weaver was awarded Purdue University's Outstanding Teaching Award. Her honors include the Purdue University Health Promotion Award for Women (1993), the Institute of Food Technologists’ Babcock Hart Award (1997), the USDA A.O. Atwater Lecture Award (2003), the NAMS/Glaxo Smith Kline Consumer Healthcare Calcium Research Award (2006), the Purdue University Sigma Xi Faculty Research Award (2006), the ASN Robert H Herman Award (2009), the Natural Products Association’s Burton Kallman Scientific Award (2010), the Linus Pauling Research Prize Award (2011), the Spirit of the Land Grant Award (2013), the Herbert Newby McCoy recipient (2012), this award is the most prestigious research honor given by Purdue University), the Trailblazer Award (2016) by the Institute of Food Technology (IFT) and the Academy of Nutrition and Dietetics (AND), an award to recognize “exceptional leaders” who have advanced the science at the interface of dietetics and food science, and the David Kritchevsky Career Achievement Award, American Society for Nutrition/ASN Foundation (2017). Weaver was appointed to the 2005 Dietary Guidelines Advisory Committee for Americans. She has published over 400 research articles to date. Weaver received a Bachelor of Science and Master of Science in food science and human nutrition from Oregon State University. She received a Ph.D. in food science and human nutrition from Florida State University and holds minors in chemistry and plant physiology. 66

Beatrice Wiafe-Addai

MD, PhD Peace and Love hospitals Founder & President, Breast Care International C.E.O Kumasi, Ghana Beatrice Wiafe Addai has 29 years experience as a Medical officer in Ghana; thus from 1989 to Date. She has been a Breast Surgeon for the past sixteen years and a consultant in Breast Cancer Management. Her training and wide scope of study as a specialist Breast Pathologist and a surgeon has placed her at a convenient position as the Chief Executive Officer and the Consultant Breast Surgeon of the Peace and Love Hospitals both in Accra and Kumasi; a specialist hospital that is championing the cause of Breast Cancer and its related diseases in Ghana. Due to her charisma, Wiafe Addai is known as a fine role model and inspiration to women and society as a whole and the quest for a unique professionalism as far as patient care and welfare are concerned. She became the first Ghanaian female specialist general surgeon. By Godâ&#x20AC;&#x2122;s grace and her endowed knowledge, hundreds of women have been healed of various diseases through her directives particularly Breast Cancer.

From a humble beginning fifteen years ago, Peace and Love Hospital now serves as a resource Centre for the Diagnosis, treatment, Counselling, Rehabilitation, and Research for Breast Cancer, Cervical Cancer, Hepatitis Infections and Renal Dialysis among others. It is in view of these, other tangible facts, and through her innovation and preoccupation with developing the infrastructure of Breast Cancer Advocacy, Breast Care International (BCI), an NGO that seeks the promotion of Breast Cancer Awareness in Ghana especially in the remote communities was concerted in 2002 in Kumasi to intensify public awareness on the disease. This Public Awareness campaign has salvaged hundreds of women from the devastating effect of Breast Cancer and its related disease and even men. On weekends (mostly on Sundays where most women could be reached), after the exhaustive week days, Wiafe Addai and her able team normally embark on outreach mission among women groups, churches, Second cycle and tertiary institutions, organizations, and those marginalized in rural and deprived communities, sometimes at the expense of her own financial 67

and logistical resources.

B. Wiafe Addai is a member of several professional bodies including the Ghana Medical Association, Surgical Society of Russia, Soviet Trained Graduates Association, and International Federation of University Women (IFUW). She is a board member for the National Health Insurance Capitation in Ashanti Region. She is also a member of the Board of Governors of Mpraeso Senior High School and the Kwahu Government Hospital, Atibie. She is currently the Chairperson of the Ghana Cancer Board and Ghana NCD Alliance. She also serves on international bodies such as IBCN, UICC, IARC, AORTIC, IBCN, Direct Relief etc.

Her passion and aspiration for the prevention, awareness and treatment of breast cancer has earned her an honorable recognition in Ghana and internationally as one of the champions advocating for the eradication of the disease. By dent of her hard work, commitment and meticulous working experience in various environments and her continuous search for better ways of delivering care for Breast Cancer patients, Wiafe-Addai has become an active international speaker. She has addressed many international conferences and symposiums sharing her rich knowledge about the disease.

Chongli Yuan

PhD Chemical Engineering Purdue University Indiana, USA Yuan got her BS degree in chemical engineering from East China University of Science and Technology in 2002. She worked with Lynden Archer at Cornell on the DNA mechanics and nanomaterial synthesis for her Ph.D. After obtaining her degree in 2007, she moved to ETH, Zurich and worked as a postdoctoral researcher at Prof. Tim Richmondâ&#x20AC;&#x2122;s group in molecular biology and biophysics. She joined the School of Chemical Engineering at Purdue University as an Assistant Professor in 2009. She has been awarded the ACS PRF new investigator award and CDMRP lung cancer concept award. Her current research primarily focuses on elucidating the epigenetic regulation mechanism in human cells and developing novel epigenomic tools to detect and quantify epigenetic modifications related with human diseases. Her research is supported by NSF, NIH and industrial sponsors.

Min Zhang MD, PhD. Department of Statistics Purdue University Indiana, USA

After obtaining an M.D. with residency in a cancer hospital and a Ph.D. in Neurophysiology, Zhang received my second Ph.D. in Biological Statistics and Computational Biology from Cornell University. Zhang is currently a professor at Purdue University in the Department of Statistics and the leader of Bioinformatics Training program of Purdue University Center for Cancer Research. By bringing expertise in biostatistics to medical research, Zhang has focused his research on developing statistical methods for analyzing high-dimensional clinical and omics data (i.e., genomics, transcriptomics, metabolomics etc.) with limited sample size that often occur in biomedical research. These methods can be employed to identify molecular signatures and construct network for understanding the molecular basis of cancer, and to predict disease risk using available predictors at molecular, pre-clinical, and population levels.

Concept Paper

The International breast cancer and nutrition project: Prevention research to reduce cancer incidence

The problem: Breast cancer incidence is rising all over the world, at different rates. Of particular concern is the rapid rise of incidence in low and middle income (LMI) countries where aggressive forms of the disease are seen in young women. The diversity in types of breast cancers can be largely explained by the heterogeneity of gene expression profiles. Gene expression is controlled by the heritage and the environment. Effective lifestyle factors and targeted therapies are practical interventions for disease prevention but have been limited for breast cancer. A recent report by the World Cancer Research Fund has confirmed the link between two nutrition-related exposures, obesity and alcohol consumption, and breast cancer incidence. However, developing countries could not be included in the compiled research due to the lack of data, nor could the rise of premenopausal breast cancer incidence be captured in the studies given their large focus in postmenopausal breast cancer. Existing epidemiological data of the relationship between diet and breast cancer poorly address the mechanisms of breast cancer initiation.

The priority: Globally, breast cancer is ranked second in terms of incidence after lung cancer. It is known that lung cancer is largely preventable. Knowing the main environmental cause of lung cancer enabled the WHO to accomplish the unprecedented step of having an international treaty on restricting tobacco use ratified by many countries. Breast cancer is usually the number one cause of mortality of all cancers in women, and is often the number one or two cause of mortality over all diseases in women on a per country basis. Unfortunately, even though the WHO labeled cancer prevention an urgent priority, especially in light of the fast rise of cancer in developing countries, noncommunicable diseases (a category to which most forms of cancer belong) continue to receive far less attention than communicable diseases. Breast cancer, a top priority noncommunicable disease, has now reached a similar level of urgency and likely is largely preventable with appropriate interventions.

The gap: The mechanisms that transition normal breast epithelium into neoplastic tissue are not understood. Only recently, have tools become available to study the breadth of epigenetic variability associated with the control of gene expression and it has not yet been applied to the relationship between environment and breast cancer. The link between diet and risk of breast cancer has not been studied in populations that encompass the diversity of diet, life style affecting energy balance and breast cancer incidence observed around the world. The link may 72

largely relate to the impact of diet on the epigenome. Biomarkers to assess prevention strategies are lacking. The whole infrastructure to do global research is underdeveloped.

The solution: Global interdisciplinary partnerships are needed to frame the questions; to study the relationship between diet and life styles, the epigenome, and breast cancer development; to describe the epidemiology of breast cancer in LMI countries; to develop and assess breast cancer prevention strategies; to develop and evaluate public health communication strategies; to create and implement appropriate cancer prevention policies. The international breast cancer and nutrition (IBCN) program initiated by Purdue University aims at promoting coordinated, yet country-tailored, breast cancer prevention research all over the world (see website for mission, goals, and infrastructure: http://www.purdue.edu/dp/ibcn ). This will be achieved notably through a program focused initially on the impact of nutrition on the epigenome, with the possibility to extend to other environmental factors. (1) Sophie LeliĂ¨vre DVM, LLM (public Health), PhD, Leader, Breast Cancer Discovery Group of the Purdue Center for Cancer Research &, Connie Weaver, PhD, Head, Department of Foods and Nutrition, and Deputy Director, Indiana Clinical and Translational Sciences Institute International Breast Cancer and Nutrition Project, Purdue University, West Lafayette, IN, USA (2) Isabelle Romieu, MD, MPH, ScD, Head, Section of Nutrition and Metabolism, International Agency for Research on Cancer, Lyon, France, (3) Francesco Branca, PhD, Director, Nutrition for Health and Development &, Cecilia Sepulveda, MD, MPH, Senior Adviser, Programme Cancer Control, World Health Organization, Geneva, Switzerland Written on September 15, 2010

Scientific Committee

Chongli Yuan, Purdue University, USA Nora Artagaveytia, Universidad de la RepĂşblica, Montevideo, Uruguay Beatrice Wiafe, Peace and Love hospitals, Kumasi, Ghana Mary Beth Terry, Columbia University, USA Graciela Sabini, Ministry of Health, Montevideo, Uruguay Rabih Talhouk, American University of Beirut, Lebanon Rihab Nasr, American University of Beirut, Lebanon Evan K Perrault, Purdue University, USA Farah Naja, American University of Beirut, Lebanon Joan Lappe, Creighton University, USA Ellen Gruenbaum, Purdue University, USA Victoria Seewaldt, City of Hope, CA, USA

Poster List

POSTER SESSION AND BUFFET DAUCH ALUMNI CENTER 403 W. WOOD STREET, PRUSIECKI BANQUET ROOM/RUDOLPH LIVING ROOM MONDAY, OCTOBER 8TH 5:30 – 8:00 PM #1

ABENA OFOSUAH: “CENTRALIZATION OF CANCER CARE: THE JOURNEY TO DIAGNOSIS OF LOCALLY ADVANCED BREAST CANCER IN GHANA”

CYAN COSBY: “ENGINEERING IN VITRO MODELS TO STUDY THE SYNERGISM OF BREAST CANCER RISK FACTORS”

DENNIS CLADIS: “MINERAL AND PHENOLIC CONTENT IN REPRESENTATIVE DIETS FROM SEVEN COUNTRIES FOR THE INTERNATIONAL BREAST CANCER AND NUTRITION PROJECT”

FARZANEH ATRIAN AFYANI: “ENHANCING THE EFFECT OF ANTICANCER DRUGS THROUGH MODIFICATIONS OF NUCLEAR MORPHOLOGY”

LAKSHYA MITTAL: “ENHANCEMENT OF BIOACTIVE COMPOUNDS FROM BLACK GRAPE EXTRACT USING PULSED ELECTRIC FIELD TREATMENT”

LIESL KRAUSE: “DIELECTRICALLY-ACCURATE TISSUE SIMULATING MATERIALS FOR A HETEROGENEOUS BREAST MRI PHANTOM”

NADIA LANMAN: “THE PCCR BIOINFORMATICS CORE: A GLANCE AT CAPABILITIES AND HIGH-IMPACT PROJECTS”

NATALY NASER AL DEEN: “DYSREGULATED MICRORNAS IN EARLY ONSET BREAST CANCER IN LEBANON AND THEIR ASSOCIATION WITH LOSS OF MORPHOGENESIS OF BREAST EPITHELIUM IN A 3D CULTURE MODEL”

NATASCIA MARINO “METABOLIC REPROGRAMMING OF THE BREAST CONTRIBUTES TO A CANCER-PROMOTING MILIEU”

#10

NATASCIA MARINO: “PROSPECTIVE RANDOMIZED STUDY OF METFORMIN FOR BREAST CANCER PREVENTION IN OVERWEIGHT/ OBESE WOMEN”

#11

RHONDA ARTHUR: “BODY FAT AND RISK OF BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH NORMAL BODY MASS INDEX”

#12

SARAH LIBRING: “ENGINEERING PLATFORMS TO INVESTIGATE CANCER METASTASIS”

#13

SHIRISHA CHITTIBOYINA: “ENGINEERING IN VITRO TECHNIQUES TO IDENTIFY RISK FACTORS FOR BREAST CANCER” 77

#14

VISHAK RAMAN: “PROTEOMIC ANALYSIS REVEALS AN EXTRACT OF THE PLANT LIPPIA ORIGANOIDES TARGETS MITOCHONDRIAL METABOLISM IN TRIPLE-NEGATIVE BREAST CANCER”

#15

SETH WIAFE: “UNMET NEEDS OF BREAST CANCER SURVIVORS IN AFRICA: NEEDS ASSESSMENT FOR DEVELOPING SURVIVORSHIP SERVICES IN GHANA AND TANZANIA”

#16

XIE ZHUOER: “EXPLORATORY METABOLOMICS AND LIPIDOMICS BY MULTIPLE REACTION MONITORING PROFILING”

Registrant List

First Name

Last Name

Email Address

Company

Primary Country

Caroline

Abadie

caroline.abadie@ico.unicancer.fr

France

Abena

Addai

abenaofosuah@gmail.com

Mope

Adeola

adeolam@purdue.edu

Institut de CancĂŠrologie de l'Ouest Breast Care International / Peace and Love Hospitals Purdue University

Tanya

Agurs-Collins

collinsta@mail.nih.gov

USA

Chaylen

Andolino

candolin@purdue.edu

National Cancer Institute/NCI Purdue University

Nora

Artagaveytia

nartagave@gmail.com

Faculty of Medicine

Uruguay

Rhonda

Arthur

rhonda.arthur@einstein.yu.edu

Albert Einstein College of Medicine

USA

Nadia

Atallah

natallah@purdue.edu

Purdue University

USA

Shweta

Athilat

sa3313@cumc.columbia.edu

USA

Farzaneh

Atrian

fatriana@purdue.edu

Columbia University Mailman School of Public Health Purdue University

Tarah

Ballinger

tarahb@iu.edu

USA

Martine

Bellanger

Martine.Bellanger@ehesp.fr

Luanne

Bermel

lmi@purdue.edu

Indiana University School of Medicine EHESP School of Public Health Women's Global Health Insitute

Laura

Bowers

bowers53@purdue.edu

Purdue University

USA

Angela

Bradbury

angela.bradbury@uphs.upenn.edu

University of Pennsylvania

USA

Ghana

USA

France USA

Marissa

Burgermaster marissa.burgermaster@austin.utexas.edu University of Texas at Austin

USA

Ignacio

Camarillo

ignacio@purdue.edu

Purdue University

USA

PierreFrancois

Cartron

pierre-francois.cartron@inserm.fr

INSERM/ICO

France

Luis

lgcarvajal@ucdavis.edu schittib@purdue.edu

University of California, Davis Purdue University

USA

Shirisha

CarvajalCarmona Chittiboyina

Dennis

Cladis

dcladis@purdue.edu

Purdue University

USA

Cyan

Cosby

ccosby@purdue.edu

Purdue University

USA

Marisa

Fazzino

marisafazzino@gmail.com

Hospital Policial

Uruguay

Rodrigo

Ferreira

ferreir@purdue.edu

Purdue University

USA

Christina

Ferreira

cferrei@purdue.edu

Purdue University

USA

Michele

Forman

mforman@purdue.edu

Purdue University

USA

John

Fry

johnfry@purdue.edu

USA

Audrey

Goldbaum

agoldbau@purdue.edu

Purdue Center for Cancer Research Purdue University

Ellen

Gruenbaum

gruenbaum@purdue.edu

Purdue University

USA

Mazin

Hakim

mhakim@purdue.edu

Purdue University

USA

Ming

he261@purdue.edu

Purdue University

USA

Andreas

Hielscher

ahh2004@columbia.edu

Columbia University

USA

Kelsey

Hopkins

hopkink@purdue.edu

Purdue University

USA

Nahla

Houalla

nahla@aub.edu.lb

Lebanon

Lauren

Houghton

lh2746@cumc.columbia.edu

Charlotte

Huet

c.huet@rennes.unicancer.fr

Violet

Kiesel

vkiesel@purdue.edu

American university of Beirut Columbia University MailmanSchool of Public Health Centre EugĂ¨ne Marquis Purdue University

Perry

Kirkham

pkirkham@purdue.edu

Purdue University

USA

Liesl

Krause

krausel@purdue.edu

Purdue University

USA

Tim

Kwok

kwokt@purdue.edu

Purdue University

USA

Sophie

Lelievre

lelievre@purdue.edu

Purdue University

USA

Sarah

Libring

slibring@purdue.edu

Purdue University

USA

Lothar

Lilge

Lothar.Lilge@Uhnresearch.ca

Canada

Michelle

Liratni

mliratni@purdue.edu

Natascia

Marino

marinon@iu.edu

University of Toronto Purdue Center for Cancer Research Indiana University

Jasmine

McDonald

jam2319@cumc.columbia.edu

USA

Lakshya

Mittal

lmittal@purdue.edu

Mailman School of Public Health, Columbia University Medical Center Purdue University

Nataly

Naser Al Deen

nmn30@mail.aub.edu

American University of Beirut

Lebanon

Rihab

Nasr

rn03@aub.edu.lb

American University of Beirut

Lebanon

USA France USA

USA USA

USA

Sampson

Nyamekye

chefnyamekye@ymail.com

Breast Care International

Ghana

Antwi

Osei Assibey

chefnyamekye@gmail.com

Ghana

Song-Yi

Park

spark@cc.hawaii.edu

Dhabaleswar Patra

dpatra@purdue.edu

Kumasi Metropolitan Assembly University of Hawaii Cancer Center Purdue University

Rahim

Rahimi

rrahimi@purdue.edu

Purdue University

USA

Vishak

Raman

ramanv@purdue.edu

Purdue University

USA

Timothy

Ratliff

tlratliff@purdue.edu

Purdue University

Les

Reinlib

reinlib@niehs.nih.gov

NIH

USA

Joseph

Rispoli

jrispoli@purdue.edu

Purdue University

USA

Jose

Rivera

riverami@purdue.edu

Purdue University

USA

Sharon

Ross

rosssha@mail.nih.gov

USA

Graciela

Sabini

gsabini@adinet.com.uy

National Cancer Institute ministry of health uruguay

Victoria

Seewaldt

vseewaldt@coh.org

City of Hope

USA

Madeline

Sheeley

powell51@purdue.edu

Purdue University

USA

Sudhanshu

Shekhar

shekhas@purdue.edu

Purdue University

USA

Sudha

Sivaram

sudha.sivaram@nih.gov

USA

Anna Maria

Storniolo

astornio@iu.edu

NIH/ Nat'l. Cancer Institute Indiana University

Raji

Sundararajan

raji@purdue.edu

Purdue University

USA

USA USA

Uruguay

USA

Rabih

Talhouk

rtalhouk@aub.edu.lb

Lebanon

watao@purdue.edu

American University of Beirut Purdue University

Andy

Tao

Dorothy

Teegarden

teegarden@purdue.edu

Purdue University

USA

Parisa

Tehranifar

pt140@columbia.edu

Columbia University

USA

Mary Beth

Terry

mt146@columbia.edu

Columbia University

USA

Sagar

Utturkar

sutturka@purdue.edu

Purdue University

USA

Donna

Vandergraff

DVANDERG@PURDUE.EDU

Purdue

USA

Pierre

Vidi

pvidi@wakehealth.edu

USA

Colby

Vorland

cvorland@purdue.edu

Wake Forest School of Medicine Purdue

Connie

Weaver

weavercm@purdue.edu

Purdue University

Seth

Wiafe

swiafe@llu.edu

USA

Beatrice

Wiafe-Addai

drwiafe@gmail.com

Zhuoer

Xie

xie214@purdue.edu

Loma Linda University Breast Care International / Peace and Love Hospitals Purdue University

Chongli

Yuan

cyuan@purdue.edu

Purdue University

USA

ChaeHyun

Yum

cyum@purdue.edu

Purdue University

USA

Min

Zhang

minzhang@purdue.edu

Purdue University

USA

Ghana

USA

Sponsor List Purdue University Center for Cancer Research International Breast Cancer & Nutrition (IBCN) Office of the Provost at Purdue University Office of Executive Vice President for Research and Partnerships Susan Bulkeley Butler Institute for the Development of Women Leaders The Catherine Peachey Fund, a Member of the Heroes Foundation Family Purdue University Department of Nutrition Science Purdue College of Veterinary Medicine Purdue College of Health and Human Sciences Purdue College of Science Purdue University Department of Basic Medical Sciences